——————————————————————
My name is Doug Olson
I’m from Nebraska
Western Nebraska
And, uh, my mother has been diagnosed with pancreatic cancer
So, we, uh, middle of November, now this is first of, first of the year, eh, but in the middle of November her weight, she was losing weight, you know
She was suffering from indigestion and, and stomach pain, and so we started to have her checked, uh, for problems with her stomach for ulcers and that kind of thing, and all that proved negative, and they put her on an ulcer medicine anyway, thinking that maybe that would solve the inflammation in her stomach, and, uh, then we decided that we (?) better see another physician, and so we did that, and they then ultra sounded and then CAT scanned and found that she had tumors in her pancreas and in her liver
Uh, many years ago, back in, in the late 70’s, my parents had been involved with, with the cancer, uh, subject in regards to my father’s sister, and then his cousin
He started researching cancer and cancer treatments when his sister passed away, and then, uh, they got in contact with a doctor in Orden, Nebraska, that treated cancer patients with Laetrile, and he also did other, not so ordinary things
He did duculation therapy
Uh, a number of things that were really treatments for the disease rather than just treatments for the symptoms, and, uh, during that time, dad testified at the state legislature; they were trying to work against Dr. Miller’s license
This was the Dr. Miller in Orden, and, uh, so dad testified on, on his behalf
Uh, dad’s cousin was, uh, a patient of his, and she had a brain tumor the size of a lemon, and Dr. Miller put her on, uh, Laetrile treatments on a, on a special diet and some things, uh
——————————————————————
And this was what, in the 70’s ?
——————————————————————
This was back in the, probably the late 70’s, and, so, when they
Well they cured her
She had been sent home from the Mayo Clinic
Given 3 to 6 months to live, and, uh, they had, uh, burned with radiation and cobalt I believe is what they were treating her with at that time
Uh, they burned the, uh, nerves in her eyes so that her eyes crossed
Uh, they sent her home to die
They, uh
She was in a wheelchair
She was a young woman and she had a young child
Wasn’t able to hold that child, and so when my dad saw her, met her, she was in that condition
She was it, in the last 6 months of her life
Gave her a book about, uh, the subject, and told her about Dr. Miller, and her family
She then went to Dr. Miller to see if there was any help for her, and he, and he immediately put her on Laetrile treatment then and, and, uh, the interesting thing about it, looking at his doctor’s protocol; because I’ve come across his protocol, uh, Dr. Miller was also giving his patients antineoplastons, and
——————————————————————
Yeah, because we’ve got this thing here that you gave me
——————————————————————
Mhmm
——————————————————————
Just explain to me what this is
——————————————————————
This was his physician’s protocol, to list, uh, the different medicines a person should, should be on
——————————————————————
If they had cancer
——————————————————————
Uh, if they had cancer, and so, uh, this was given to another friend of ours, a friend of the family, uh, the folks that rented one of our properties, uh, the woman got a, a tumor as well, and this was given to her as part of the regimen she should follow, and she was given Laetrile injections, and then as soon as the injections, uh, were over they went then to pills as the size of the dosage went down, and when you got to pills you got to go home
So, uh, I remember speaking to her at the time
I had a
I was in high school, and I had a summer job with her husband, who was the county engineer
So, uh, we saw them all the time, and she told us, uh, the circumstances when, when she was allowed to come home
She was feeling strong
She said: “I haven’t felt better”
As a part of the diet and the things that, that they had her doing
She said she felt better than she had in many years
So she and her daughter, started a business in town in order to pay for the treatments, and, uh, she recovered
The tumor continued to shrink and shrink until it was nothing
Uh, what had been listed as inoperable, uh, after it shrunk halfway they decided, well maybe we can operate on you
Uh, we think it’s operable now
She said: “Why would I let you operate when what I’m doing is working” ?
But, uh, she is alive yet today and in her mid-80’s and, uh, so, uh, when it came to my mother’s illness, we contacted her, and asked her how she’s doing, and she’s sent this protocol she’s been keeping all these years
Uh, as a result of my parents knowing Dr. Miller back when he was alive
He is, he has passed away, uh, 7 maybe years ago, and, uh, many years ago when they were taking chelation therapy from him, he had given my mother, uh, a flyer on Dr. Burzynski, and, uh, said if anything ever happens to you after I’m gone, this is the man to contact, and so we’ve had that flyer in a file for many years at my parents house, and so when mom got sick she immediately began digging that out and found
——————————————————————
So your mom immediately started thinking, well I need to find that leaflet
That’s what we were told to do
——————————————————————
Yes
——————————————————————
And did, and did she go and speak to an oncologist ?
Did she say that she wanted to come here, or ?
——————————————————————
We had a local physician, who was not an oncologist, that had, that was the 2nd physician we, we consulted, that did the ultrasound and the CAT scan for her and, and they knew that she had tumors, and no we did not go to an on, oncologist from there
——————————————————————
Why ?
——————————————————————
because we knew that we did not want to take their treatments, uh, so we immediately contacted the clinic here in, in Houston, Texas, and, uh, we had to wait on, uh, certain things to be completed
CAT scans
Different things had to be done, and, and information had to be sent down here and examined, and then, uh, after a period of maybe 2 weeks, hassling with information, we were told that, yes, uh, we, they would accept her as a patient, and we were getting in towards the holidays at that time
Would we like to wait until the holidays were over, because Christmas
You know, there would be 5 days off for Christmas, uh, over a weekend and 5 days off for New Years over a weekend, and we would be down here in Houston over those times, but we elected to come anyway because we could get the treatment started right away
——————————————————————
Mhmm
——————————————————————
rather than to wait another month before starting treatments, and, uh, so they, uh, immediately put, put her on antineoplastons and, uh, they sent away the tissue samples to Arizona to have a CARIS test done, and determine what medications would be
——————————————————————
So did you have those results come back ?
——————————————————————
Yes, those results came back quicker than what we expected
——————————————————————
And wh, what did they show ?
——————————————————————
Well they, they show a, a list of treatments that are effective, and against it, and then a list of treatments actually that encourage it’s growth
——————————————————————
Yeah
——————————————————————
So you end up with a list of, uh, approximately 7 on each side
7 good
7 bad
——————————————————————
And these are all different cancer drugs
So what they’re looking at is all
——————————————————————
Yes
——————————————————————
is all the different cancer drugs, and which ones
——————————————————————
And whether we’ve got a, a thousand or 2 thousand different drugs that person might try, and, uh, so
——————————————————————
So the (?) for how to, to try a few of these chemotherapies, but in very small doses
Is that right ?
——————————————————————
There’s 2, 2 chemotherapies
One is an, is an oral chemotherapy that is, uh, quite mild in its side effects, and then, uh, there’s another much stronger one that was, uh, also one of th, the top 2, and, uh, the side effects for it are more varied and more violent, uh, if you will, and, uh, my mother’s had one treatment of that so far, and the treat, the side effects
She did, is suffering from side effects from that particular
——————————————————————
Yeah
——————————————————————
It’s Oxaliplatin, and, uh, some people have very violent side effects but she’s thankfully not had any violent side effects
——————————————————————
So why didn’t you go down the conventional road of having high-dose chemotherapy ?
——————————————————————
Well, when you research the, uh, success rate, with pancreatic cancer, going the normal way, uh, or the normal, uh, road, the success rate is very, very small, and so you’re just guaranteeing, in my opinion, if, if the success rate is 5% or under, uh, you’re introducing yourself to a, a road to death, that’s very unpleasant
——————————————————————
Yeah
——————————————————————
You know, you just want to go home and make yourself very comfortable on painkillers and, and enjoy the rest of your life, uh, if that’s the, if that’s the road you’re planning to take
——————————————————————
Yeah
——————————————————————
Uh, that was our opinion, and so
——————————————————————
What do you think about all the resistance then of, of Dr. Burzynski and all of the kind of, uh, ?
——————————————————————
We have
——————————————————————
(?) people just calling him a
What’s the word ?
——————————————————————
Charlatan
——————————————————————
Charlatan
Yeah
Fraud
——————————————————————
Yes, we, uh, we have seen course, of course these things through our, our life
Dr. Miller
The whole Laetrile treatment thing was something that was, uh, thrown out
You know, it’s pretty well suppressed now
You can go to Mexico and get those treatments
——————————————————————
Why do you think they were, pushed aside ?
This Laetrile
——————————————————————
It’s
——————————————————————
What is Laetrile ?
——————————————————————
Well Laetrile is a naturally occurring, uh, substance that you find in some of our foods
It’s, they call it B17 although, vitamin B17, although there’s some discussion as to whether it’s really a vitamin
Another name for it is Amygdalin
——————————————————————
Amygdalin
Yeah
——————————————————————
Uh, it’s found in peach pits and apricot pits in high levels but there’s a number of other foods that you find it in
Uh, it, it,
I’m not sure, whether this is 100% accurate, but my understanding of it is it’s associated with, with cyanide, and it would be, uh, like an encapsulated cyanide, that as it travels through your body, the cyanide portion, um, does not become available to your body until it becomes in, uh, associated with a cancer cell
——————————————————————
Yeah
——————————————————————
and the cancer cells attack the outer shell of that molecule, and the cyanide becomes, uh, uh, available then, and it kills the cancer cell that’s right there
So it was apparently a very nontoxic substance
Uh, you have regulated dosages
I mean, it seems to me interesting, uh, when a doctor prescribes a dose of chemotherapy, uh, there’s nothing that I can think of much more toxic than a, than a chemotherapy drug, and certainly they’ll kill you if they don’t, uh, give you the right dosage, but it was not seemed, deemed accessible that a byproduct of food; which a doctor could regulate the dosage of as well, could be used as a transfer, cancer treatment
——————————————————————
Yeah
——————————————————————
Uh, and we’ve seen things in the past, as well
When I was a, a very young child, I had a great aunt, that, uh, I was not even aware; at the time I was very young, she was traveling to Texas and getting treatments
Uh, one of them was called the Hoxsey treatment and, uh, she was living a very comfortable life on treatments that she got there
There were 2 treatments in Texas at that time, that, uh, were available
The FDA would come in and raid the clinics, and make just life miserable for them
They got one of them closed down, and that was the one that my great aunt was on, and that treatment was, was pills that she could take, uh, and live quite comfortably, in Nebraska
Once they closed that clinic down, then she had to go down, uh, to the other clinic in Texas, which was a supplement that was a liquid that tasted bad, and she had to make frequent trips, at that point, but still, as long as she could get that treatment she was comfortable and, and lived a normal life
A productive life
Uh, we knew her as our great aunt and, and didn’t even know her, uh, uh, that there was a health problem and, uh, but then the FDA got that clinic closed down
So, as soon as she lost access to those, her treatments, then her cancer which, uh, was no longer able to be controlled, came back strong and, and she died
So, uh, the family had been, had access to this knowledge and this, the FDA’s games with cancer treatments for many years
Um, I’m also married to, a, a gal whose father did blood research as a, he was a Ph.D and worked in university hospitals, in blood research all of his life
He, he discovered a blood protein that was associated with cancer
Uh, it was actually associated more with good health, maybe than you could say with cancer, but he discovered a, a blood coagulation protein, uh, or associated with blood coagulation that would, that could be used as a flag or a test, to see whether a person was healthy or not
Uh, as they applied it to patients in these hospitals, during their research trials, they found that this protein was an indicator whether a person had cancer or thrombosis
Uh, 2 of the very largest killers, and this protein, if present in high enough amounts in our blood, uh, was an indicator that you were healthy, and as the protein’s amount, uh, declined, then it was an indicator that something was wrong, and below a certain amount you knew something was wrong
You better be taking further testing
——————————————————————
Mhmm
——————————————————————
to find out what your problem was
Uh, that has run into resistance
Uh, that (?) has not been approved by the FDA, and, uh, th, our family’s experiences with cancer treatments, cancer drugs, as they’re affected by the FDA, we have determined by our opinion that, uh, it’s, un, unless there’s something that’s going to generate a, a lot of capital, and then a lot of tax money for the Federal Government, the FDA’s not very interested in it
——————————————————————
Yeah
——————————————————————
Uh, so, cynical attitude, but evidence bears it out
——————————————————————
Yeah
——————————————————————
and so we remain cynical until so, until something proves
——————————————————————
Yeah, absolutely
So this is this doctor in, uh, in the 70’s
This is information that he provided
——————————————————————
Yes
——————————————————————
and you can see here that he is obviously, antineoplastic enzymes
See, here obviously
Do you think he meant Dr. Burzynski ?
He just knew of him ?
You have no idea ?
——————————————————————
I have no idea
——————————————————————
He was obviously a fan, if he was someone that eventually said
He said it to you
Did you say he said it to your mum or to your dad?
——————————————————————
To my mom
Probably to mom and dad
——————————————————————
Yeah
——————————————————————
Uh, my mom was the record keeper, and so, she kept the flyer
——————————————————————
Yeah
——————————————————————
but they both took, uh, the, uh, the therapy from, uh, well, the blood therapy
I mentioned it earlier
Suddenly the name’s gone away
——————————————————————
Yeah
——————————————————————
but, uh
——————————————————————
That’s ok
——————————————————————
So
——————————————————————
So what about, um
You know, one of the barriers that we had is, when we spoke to oncologists, they just said, no, you mustn’t come to see this guy
His work isn’t peer-reviewed
He’s a charlatan
Why, why do you think they would say that ?
What
I mean I’m surprised, that these oncologists don’t actually come here, to actually see what, what’s going on
So your opinion about that ?
——————————————————————
My opinion is, that physicians are, very much, tied up, with large pharmaceutical corporations
Uh, I spoke with my father-in-law
My father-in-law had to have research done in, in his Ph.D work, and he had to get cooperation from hospitals, from doctors, and, uh, all of these organizations in order to have the research done that he needed done, ’cause past his lab, when he wants to introduce research, onto a patients, uh, live blood, and he needs to collect specimens from patients, then a whole ‘nother group of, uh, set of authorizations have to be signed and, and he being a Ph.D working with the medical profession all his life, he knew how tied up the medical profession is, by, generally by M.D.’s, that control the money flow, uh, in the medical profession
Ph.D’s do the research, but they have to apply for grants, and typically the grants are controlled by M.D.’s, and so if an M.D. Decides that your, your particular research is either applicable to, uh, something they think will make a lot of money, or it’s the, the quote, uh, popular, popular item of the day
——————————————————————
Yeah
——————————————————————
Politically correct, you name it, then you’re going to get funded
Otherwise, uh, my father-in-law noticed at different times, his research had to be funded out of his own pocket, and at other times, it looked like, it was something that doctors would like, and so they would, he would get funding, but I think that, ah, as he commented, any doctor, coming out of med school, has been contacted by a pharmaceutical company, and has probably signed a contract, that when that pharmaceutical company wants to test a drug, or test an item, that that medical, uh, doctor, will be accessible to them, to test their products
So, with the number of pharmaceutical companies that you have, and all of them recruiting M.D.’s as they come out of med school, and saying, you know, would you be part of our group, you end up under contract with the large pharmaceutical companies
——————————————————————
Mhmm
——————————————————————
and if, if 90% of the doctors are under contract with pharmaceutical companies, to, uh, to cooperate with their drug testing, then large Pharma, has control of virtually all doctors, and so, uh, uh, if you have large Pharma saying, we don’t want to see a cancer cure, that we’re not in control of, we don’t want to see something that makes curing disease cheap, and easy, and food related, then you’re not gonna
They’re going to put the word out to all their doctors: Don’t have any wo, don’t have anything to do with this
Uh, they can come up with, some written material for their, their doctors to read
They send them the evidence
——————————————————————
Mmm
——————————————————————
It may be accurate
It may not be very accurate, and, uh, but it’s just a smear campaign to destroy reputations so that they don’t get hurt financially
——————————————————————
Mhmm
——————————————————————
and, uh, so, uh, that’s the reason I believe
You know, most of these doctors, they don’t have the time, or the expertise to do the research themselves
They can’t read everything, and so when someone they trust, or someone that they’re financially, uh, obligated to, comes down and says: Here’s the stand that we want you to take, and it’s against this particular treatment, or against this doctor, they do what they’re told
——————————————————————
Yeah
——————————————————————
They do what they know best
Uh, my father-in-law, for instance, was, uh, also involved as a professor in these med centers
He taught nutrition, and he said it’s always a, been amazing to me that you can get through med school, and never take a class on, on nutrition
So you can become an M.D., and not understand the value, of nutrition, to a person’s health
That’s a problem
Uh, he recognized it as a problem
I recognize it as a problem because I particularly believe that most of our ill health is because how we treat our bodies
What we eat
——————————————————————
Mhmm
——————————————————————
Whether we exercise or don’t
Whether we provide our body with a way to flush the poisons or not
Uh, healthy living, and if you don’t teach our medical profession, healthy living, how can they teach their patients
——————————————————————
Mhmm
——————————————————————
So this, this whole system is, is just flawed in some ways, and weak in other ways, and, uh, controlled, for the purposes of commerce, instead of the public
——————————————————————
Yeah
So you, you think it’s a good idea treating people as an individual and finding out what they need as opposed to like carpet bombing them ?
——————————————————————
Absolutely
When we understood the, the individualized approach, here at the Burzynski Clinic, that they would take where they would test the cancer cells, uh, against all of these treatments and all of these chemotherapy treatments and, and anything else that might be out there that would, would treat cancer, and come back with a, a individualized care approach to the individualized cells of cancer that my mother has, that’s when we knew that we had to come here
We wondered, and I’ve told my friends, and everybody wonders, that oughta be the standard approach everywhere
Why wouldn’t you test, every cancer, and see what it is that’s gonna treat it best ?
You, you tell me
======================================
Doug Olson chats with Pete Cohen
January 2011
25:00
11/9/2012
——————————————————————
======================================
Tag Archives: medications
Cancer: It’s what’s Best for Business (WW3 – World War Hypocrisy)
David H. Gorski, M.D., Ph.D., F.A.C.S., is a racist and a natural born killer
That’s right !
Dr. Gorski hates #cancer
He’s a bigot when it comes to breast cancer
Gorski sleeps, breathes, and blogs about breast cancer
He is an academic surgical oncologist specializing in breast surgery and oncologic surgery (Surgical Oncology Attending) at the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan specializing in breast cancer surgery, where he also serves as team leader for the Breast Cancer Multidisciplinary Team (MDT) at the Barbara Ann Karmanos Cancer Center, Co-Chair, Cancer Committee, Barbara Ann Karmanos Cancer Center, medical director of the Alexander J. Walt Comprehensive Breast Center at the Barbara Ann Karmanos Cancer Center (2010-present), Co-Leader of the Breast Cancer Biology Program, and the American College of Surgeons Committee on Cancer (ACS CoC) Cancer Liaison Physician as well as Associate Professor of Surgery at the Wayne State University School of Medicine; Faculty (2008-present), and member of the faculty of the Graduate Program in Cancer Biology at Wayne State University, MiBOQI project director (clinical champion) for Karmanos Cancer Center, site project director of the Michigan Breast Oncology Quality Initiative, University of Michigan, Ann Arbor, Michigan, a partnership between Karmanos and the University of Michigan, the new program co-director (Co-Medical Director) of the Michigan Breast Oncology Quality Initiative (MiBOQI); a state-wide initiative to improve the quality of breast cancer care using evidence-based guidelines, serves as the co-director of the Comprehensive Breast Center and is co-leader of the Breast Cancer Biology Program at Karmanos and Wayne State University School of Medicine, a Wayne State University Physician Group surgeon and chief of the Section of Breast Surgery (Breast Surgery Section) for the Wayne State University School of Medicine (2009-present), serves as an associate professor of surgery and Oncology at Wayne State University School of Medicine, Detroit, Michigan, and Treasurer and on the Board of Directors, and also serves the Institute for Science in Medicine as head of its childhood immunization committee
Prior to joining Karmanos and Wayne State University School of Medicine, was an associate professor of surgery at The Cancer Institute of New Jersey and the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ, as well as a member of the Joint Graduate Program in Cell & Developmental Biology at Rutgers University in Piscataway, N.J.
1984 – Graduation with Honors and High Distinction in Chemistry
1994 – MetroHealth Medical Center Resident Research
He attended the University of Michigan Medical School, received his B.S. in chemistry from the University of Michigan, Ann Arbor, Michigan, medical degree (M.D.) from the University of Michigan Medical School, Ann Arbor, Michigan, University of Chicago Fellowship, Surgical Oncology, Case Western Reserve University / University Hospitals Case Medical Center Internship, General Surgery, Case Western: Reserve University / University Hospitals Case Medical Center Residency, General Surgery, and received his Ph.D. in cellular physiology at Case Western Reserve University, Cleveland, Ohio
1998 – American Board of Surgery
Assistant Professor of Surgery UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey
1999 – 2006: Assistant Professor of Surgery
1999 – 2008: Active, Surgical Oncology and General Surgery
2005 – 2006: Active, Surgical Oncology and General Surgery
2007 – American Society of Clinical Oncology Advanced Clinical Research
2007 – Conquer Cancer Foundation of ASCO and Breast Cancer Research Foundation Advanced Clinical Research Award in Breast Cancer
2006 – 2008: Associate Professor of Surgery
Faculty, General Surgery, St. Peter’s University Hospital, New Brunswick, New Jersey
Attending Surgeon, Trauma Services, Lutheran General Hospital, Park Ridge, Illinois
2015 – Michigan State Medical License (Active through)
2015 – Ohio State Medical License (Active through)
Managing Editor of the Science-Based Medicine weblog, as well as a once-weekly contributor
SBM exists to take a skeptical, science-based view of medicine in general and in particular the infiltration of pseudoscientific practices into medicine, even in academic medical centers
These entities must have felt lucky to add a University of Michigan alum to their toolbox, a wolverine; a creature also known as a glutton or skunk bear
Who would doubt that Gorski would be a glutton for punishment when it comes to raising a big stink about breast cancer issues ?
Surely he was aware: Detroit, Michigan; the most populous city in the state of Michigan, with a population of 701,475 (2012) (9,883,360 – Michigan), 575,321 (81.4%) being African American (Black); a little less than six times the national average (82.7% – 2010 / about 83% – 2012) (Michigan – 14.2% – 2010), 369,616 Females (52.7% – 2012 / 53% – 2010) (Michigan 50.9%)
No doubt he knew that the most recent American Cancer Society Cancer Facts & Figures, noted:
——————————————————————
• Studies have documented unequal receipt of prompt, high-quality treatment for African American women compared to white women
• African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective
• African Americans and other racial minorities are underrepresented in clinical trials, which makes it more difficult to assess efficacy of cancer therapies among different racial/ethnic groups
• African Americans have highest death rate and shortest survival of any racial and ethnic group in US for most cancers
• Life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years)
• Higher death rate in African American women compared to white women occurs despite lower cancer incidence rate
• Racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women
• African American women have higher death rates overall and for breast and several other cancer sites
• African Americans continue to have lower 5-year survival overall:
69% – whites
60% – African Americans
and for each stage of diagnosis for most cancer sites
• Evidence aggressive tumor characteristics more common in African American than white women
——————————————————————
Gorski worked tirelessly to address the problem, by appearing on TV, radio, Internet radio, in articles and on his blogs
Soon, the locals were remarking about the “Gorski Patient Group” web-site which was set up to display anecdotal stories of breast cancer patients who were “cured” by Gorski
How has his hard work paid off ?
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
African American women breast cancer death rates per 100,000 (MICHIGAN)
—————————————————————–
34.3☝2005_-_2009 (State with 11 most) 2013-2014
33.8👇2003_-_2007 (State with 11 most) 2011-2012
34.7👇2001_-_2005 (State with 17 most) 2009-2010
35.4👇2000_-_2003 (State with 19 most) 2007-2008
36.2👇1997_-_2001 (State tied with 20 most) 2005-2006
——————————————————————
BREAST CANCER
——————————————————————
WHITE-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
118.7👇2006_-_2010 (2013-2014)
120.1👇2004_-_2008 Incidence (2011-2012)
124.3👇2002_-_2006 (2009-2010)
129.9👇2000_-_2004 (2007-2008)
133.9☝1998_-_2002 (2005-2006)
132.1☝1996_-_2000 (2003-2004)
——————————————————————
WHITE-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
22.8👇2006_-_2010 (2013-2014)
23.4👇2003_-_2007 Mortality (2011-2012)
23.8👇2002_-_2006 (2009-2010)
24.6👇2000_-_2004 (2007-2008)
25.9👇1998_-_2002 (2005-2006)
27.3👇1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
119.4☝2006_-_2010 (2013-2014)
119.2👇2004_-_2008 Incidence (2011_-_2012)
121.0☝2002_-_2006 (2009-2010)
119.0👇2000_-_2004 (2007-2008)
120.6👇1998_-_2002 (2005-2006)
121.4☝1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
34.3☝2006_-_2010 (2013-2014)
33.8👇2003_-_2007 Mortality (2011-2012)
34.6👇2002_-_2006 (2009-2010)
35.0👇2000_-_2004 (2007-2008)
36.0👇1998_-_2002 (2005-2006)
36.9👇1996_-_2000 (2003-2004)
——————————————————————
HISPANIC-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
80.1👇2006_-_2010 (2013-2014)
92.7☝2004_-_2008 Incidence (2011-2012)
——————————————————————
HISPANIC-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
15.8☝2006_-_2010 (2013-2014)
14.26☝2003_-_2007 Mortality (2011-2012)
——————————————————————
INCIDENCE-MICHIGAN (per 100,000) COMBINED
——————————————————————
119.4☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
118.7👇2006_-_2010 WHITE (2013-2014)
80.1👇2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MORTALITY-MICHIGAN (per 100,000) COMBINED
——————————————————————
34.3☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
22.8👇2006_-_2010 WHITE (2013-2014)
15.8☝2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MICHIGAN – Estimated New Breast Cancer Cases:
——————————————————————
8,140☝2013 (State with 8th most)
7,710👇2012 (State with 8th most)
7,890☝2011 (State with 8th most)
7,340☝2010 (State with 8th most)
6,480☝2009 (State with 8th most)
6,120👇2008 (State with 9th most)
7,210👇2005 (State with 9th most)
7,270👇2004 (State with 9th most)
7,500☝2003 (State with 8th most)
7,300☝2002 (State with 8th most)
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
MICHIGAN – Estimated Breast Cancer Deaths:
——————————————————————
1,360☝2013 (State with 8th most)
1,350☝2012 (State with 8th most)
1,320 – 2011 (State with 9th most)
1,320👇2010 (State with 10th most)
1,350☝2009 (State with 9th most)
1,310 👇2008 (State with 9th most)
1,320 👇2007 (State with 9th most)
1,360 👇2006 (State with 9th most)
1,380☝2005 (State with 9th most)
1,350👇2004 (State with 9th most)
1,400 – 2003 (State tied with 8th most)
1,400☝2002 (State tied with 8th most)
——————————————————————
MICHIGAN – Cancer Incidence Rates
——————————————————————
120.3 – 2013 (State with 32nd most)
120.3👇2012 (State with 30th most)
122.2👇2011 (State with 24th most)
124.2👇2010 (State with 17th most)
127.0👇2009 (State with 11th most)
128.8👇2008 (State with 13th most)
129.4👇2007 (State tied with 18th most)
132.4👇2006 (State with 14th most)
133.5☝2005 (State with 13th most)
132.0☝1996_-_2000 (State with 14th most) 2004
129.8☝1995_-_1999 (State with 23rd most)(31st State’s) 2003
109.9👇1994_-_1998 Michigan – Cancer Incidence Rates (2002)
132.0☝1996_-_2000 (State with 14th most) (2004)
129.8☝1995_-_1999 (State with 23rd most) (2003)
109.9☝1994_-_1998 (State with 20th most) (2002)
——————————————————————
MICHIGAN – Cancer Death Rates:
——————————————————————
24.0👇2013 (State tied with 11th most)
24.4👇2012 (State tied with 13th most)
24.5👇2011 (State tied with 16th most)
25.1👇2010 (State tied with 12th most)
25.3👇2009 (State tied with 17th most)
25.8👇2008 (State tied with 18th most)
26.6👇2007 (State tied with 14th most)
27. 5 – 2006 (State tied with 12th most)
27.5👇2005 (State tied with 13th most)
28.4👇1996_-_2000 (State tied with 14th most) (2004)
29.5☝1995_-_1999 (State tied with 14th most) 2003
24.8☝1994_-_1998 (State with 14th most) 2002
——————————————————————
The problem, is that, when the Hippocratic Oath
was mentioned, Gorski may have opted for the Hypocrite Oath
Rather than address the BILLIONS of dollars in fines which Big Pharma racked up, and Pharma’s seeming dedication to getting members of the unwitting public, to take medications for symptoms which they were not approved for; and thus possibly experience adverse effects those drugs cause, Gorski chose to NOT comment about his goose that might lay the golden (parachute) nest egg
Instead, he tried the Tricky-Dicky trickle-down theory of Hackademic Mudicine (“Quackademic Medicine”); which did NOT work when Richard Milhous (“War on Cancer”) Nixon was told:
“There’s a cancer on the Presidency”
What Gorski seems hilariously oblivious to, is that his opprobrium; to turn a phrase, applies to him:
——————————————————————
(.3:16)
——————————————————————
When he mentions:
“ineffective and potentially harmful medical practices that were not, that are not supported by evidence”
he may as well be saying, in regards to surgery, chemotherapy, and radiation:
“ineffective and potentially harmful medical practices that were, that are supported by evidence“
(the evidence that they do NOT work for everyone)
——————————————————————
(.3:42)
——————————————————————
To use his own words, he seems:
“confused, at best”
——————————————————————
(.4:45)
——————————————————————
He also displays:
“an animosity toward reason”
——————————————————————
(.4:49)
——————————————————————
“Nothing’s changed within 30 years
If anything, it’s worse”
——————————————————————
(.6:45)
——————————————————————
He states:
“Alternative = unproved”
There goes “Alternative Rock,” or the “alternative” to an attempted Gorski joke: “happiness is a warm gun”
I’m somewhat surprised that Gorski has yet to classify antineoplastons as “Homeopathy: Ultra-diluted chemotherapy”
——————————————————————
(28:15)
——————————————————————
But he does rant that rival Cleveland Clinic where he had his residency, has been infiltrated by the Q.M.
——————————————————————
(39:10)
——————————————————————
And that his alma-mater, the University of Michigan has also queued in the “Quackademic” line
——————————————————————
(44:00)
——————————————————————
He bemoans the mighty wolverine:
“Again my alma-mater”
“I hang my head in shame”
——————————————————————
(44:10)
——————————————————————
And to add injury to insult, his “former employer,” UMDNJ (University of Medicine and Dentistry of New Jersey)-Robert Wood Johnson Medical School, New Brunswick, New Jersey, has also been bitten by the Quackademic Duck
I’m sure Gorski will be able to formulate a usual factoid #fail for his #failure to “cure” cancer, vis-a-vis “Orac”, the literary Hack, braying in the wilderness and awaiting his Red Badge of Courage
Maybe “too many people copulating” in Detroit, or too many Louisiana hurricane Katrina survivors added to the sandbox
Is Gorski a racist ?
That’s up to all the African American women in Detroit, Michigan, to decide
Maybe he’s just a really bad hypocrite
NOr, maybe he needs to spend less time on the “hypocuresy,” and more time on the “CURE”
Maybe the African American women of Detroit, Michigan, and the United States of America should ask Gorski:
What have you done for me lately ?
——————————————————————
——————————————————————
“And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise”
——————————————————————
NO, Gorski, the United States’ 5th Circuit Court of Appeals claimed that antineoplastons (ANPs) are:
“…an unapproved drug, not ordinary “chemotherapy”
no matter how much YOU try to claim otherwise
What are you ?
A Saul Green closet communist who does NOT believe what the United States’ Federal Courts rule ?
——————————————————————
“Indeed, it was a blatant ploy, as Burzynski’s lawyer, Richard Jaffe, acknowledged, referring to one of his clinical trials as a “joke” and the others as a way to make sure there was a constant supply of new cancer patients to the Burzynski Clinic“
——————————————————————
——————————————————————
” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials“
“As a result of the expansion of Dr. Burzynski’s medical practice, the financial condition of the medical practice has improved Dr. Burzynski’s ability to fund the Company’s operations”
——————————————————————
GorskGeek, my citations, references, and / or links, beat your NON-citations, NON-references, and / or NON-links
======================================
AMERICAN CANCER SOCIETY:
CANCER FACTS & FIGURES (2002-2014)
======================================
2002_-_2003 – 1 of every 4 deaths
======================================
Deaths – United States of America
——————————————————————
2013 – almost 1,600 a day
2002-2012☝1,500+ a day
——————————————————————
Expected to Die – United States
——————————————————————
2013☝580,350_-_(3,160 more than 2012)
2012☝577,190_-_(5,240 more than 2011)
2011☝571,950_-_(2,460 more than 2010)
2010☝569,490_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008)
2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005)
2005☝570,280_-_(6,580 more than 2004
2004☝563,700_-_(7,200 more than 2003)
2003☝556,500_-_(6,000 more than 2002)
2002☝555,500
——————————————————————
Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (1,940 less than 2012)
2012☝275,370 (3,850 more than 2011)
2011☝271,520 (1,230 more than 2010)
2010☝270,290 (490 more than 2009)
2009👇269,800 (1,730 less than 2008)
2008☝271,530 (1,430 more than 2007)
2007👇270,100 (3,460 less than 2006)
2006👇273,560 (1,440 less than 2005)
2005☝275,000 (2,190 more than 2004)
2004☝272,810 (2,210 more than 2003)
2003☝270,600 (3,300 more than 2002)
2002_-_267,300
——————————————————————
Estimated cancer deaths – African Americans expected to die from cancer:
——————————————————————
2013👇64,645 – 22.6% (2013-2014)
2011☝65,540 (About) (2011-2012)
2009☝63,360 (About) (2009-2010)
2007☝62,780 (About) (2007-2008)
——————————————————————
Estimated Breast Cancer Deaths (Women)
——————————————————————
2013☝39,620 (14%) (110 more than 2012)
2012👇39,510 (14%) (10 less than 2011)
2011👇39,520 (15%) (320 less than 2010)
2010👇39,840 (15%) (330 less than 2009)
2009👇40,170 (15%) (310 less than 2008)
2008☝40,480 (15%) (20 more than 2007)
2007👇40,460 (15%) (2007-2008) (510 less than 2006)
2006☝40,970 (15%) (560 more than 2005)
2005☝40,410 (15%) (300 more than 2004)
2004☝40,110 (15%) (310 more than 2003)
2003☝39,800 (15%) (200 more than 2002)
2002 – 39,600 (15%)
——————————————————————
Estimated Deaths from Breast cancer expected to occur among African American women:
——————————————————————
6,080☝2013 – 19% (2013-2014)
6,040☝2011 – 19% (2011-2012)
6,020☝2009 – 19% (2009-2010)
5,830☝2007 – 19% (2007-2008)
5,640☝(2005-2006)
5,640 – 1969-2002 – 18.4% – 2005 (2005-2006)
======================================
New Cancer Cases Expected to be diagnosed – USA
——————————————————————
2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)
2008👇1,437,180 – ( 7,740 less than 2007)
2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002☝1,284,900
——————————————————————
Estimated New Cancer All (Women)
——————————————————————
2013☝805,500 – (14,760 more than 2012)
2012☝790,740 – (16,370 more than 2011)
2011☝774,370 – (34,430 more than 2010)
2010☝739,940 – (26,720 more than 2009)
2009☝713,220 – (21,220 more than 2008)
2008☝692,000 – (13,940 more than 2007)
2007👇678,060 – (1,450 less than 2006)
2006☝679,510 – (16,640 more than 2005)
2005👇662,870 – (5,600 less than 2004)
2004☝668,470 – (9,670 more than 2003)
2003☝658,800 – (11,400 more than 2002)
2002_-_647,400
——————————————————————
Estimated New invasive Breast Cancer Cases: (Women)
——————————————————————
2013☝232,340 (29%) (5,470 more than 2012)
2012👇226,870 (29%) (11,610 less than 2011)
2011☝238,480 (30%) (31,390 more than 2010)
2010☝207,090 (28%) (14,720 more than 2009)
2009☝192,370 (27%) (9,910 more than 2008)
2008☝182,460 (26%) (3,980 more than 2007)
2007👇178,480 (26%) (2007-2008) (34,440 less than 2006)
2006☝212,920 (31%) (1,680 more than 2005)
2005👇211,240 (32%) (4,660 less than 2004)
2004☝215,900 (32%) (4,600 more than 2003)
2003☝211,300 (32%) (7,800 more than 2002)
2002_-_203,500 (31%)
——————————————————————
Estimated new cases – new cancer cases expected to be diagnosed among African Americans:
——————————————————————
2013☝176,620 (2013-2014)
2011☝168,900 (About) (2011-2012)
2009👇150,090 (About) (2009-2010)
2008☝182,460 (26%)
2007_-_152,900 (About) (2007-2008)
——————————————————————
Estimated new cases of in situ breast cancer expected to occur:
——————————————————————
64,640☝(2013) (1,340 more than 2012)
63,300☝(2012) (5,650 more than 2011)
57,650☝(2011) (3,640 more than 2010)
54,010👇(2010) (8,270 less than 2009)
62,280👇(2009) (5,490 less than 2008)
67,770☝(2008) (5,740 more than 2007-2008)
62,030☝(2007-2008) (50 more than 2006)
61,980☝(2006) (3,490 more than 2005-2006)
58,490👇(2005-2006) (900 less than 2004)
59,390☝(2004) (3,690 more than 2003)
55,700☝(2003) (1,400 more than 2002)
54,300☝(2002)
——————————————————————
Estimated New Cancer Cases – African Americans – Breast
——————————————————————
2013☝27,060 – 33% (2013-2014)
2011☝26,840 – 34% (2011-2012)
2009☝19,540 – 25% (2009-2010)
2007☝19,010 – 27% (2007-2008)
19,240 – 1979-2001 – 29.9% – 2005 (2005-2006)
——————————————————————
Estimated new cases of in situ breast cancer expected to occur = detection of below # of ductal carcinoma in situ (DCIS):
——————————————————————
54,944 (2013)
85% (2003-2012)
88% (2002)
1998-2002 accounted for about 85% of in situ breast cancers diagnosed (2005-2006)
1980-2001 – Incidence rates of DCIS increased more than sevenfold in all age groups, although greatest in women 50 and older (2005-2006)
——————————————————————
LEADING CAUSE OF DEATH
——————————————————————
2013 – breast cancer expected to be most commonly diagnosed cancer in women
——————————————————————
BREAST CANCER – 2nd
——————————————————————
2013 – Breast cancer 2nd most common cause of cancer death among African American women, surpassed only by lung cancer (2009-2012)
(2007)
——————————————————————
2003 – Breast cancer is 2nd among cancer deaths in women
2002-2003: 2nd leading cause of death
2002 – Breast cancer 2nd leading cause of death
————————————-
Breast cancer most common cancer among African American women
34% – (2011-2012)
25% – (2009-2010)
2007
——————————————————————
2011 – New Cases
(2011-2012)
New Cases: Breast cancer most commonly diagnosed cancer among African American women
——————————————————————
BREAST CANCER – AFRICAN AMERICAN WOMEN
——————————————————————
34% – African American women most common cancer (2011-2012)
African American Women Most common cancer (2005-2006)
——————————————————————
2005 – African American women – more likely to die from at any age
——————————————————————
ESTIMATED WOMEN BREAST CANCER DEATHS
——————————————————————
19% – number of cancer deaths breast cancer in women (2007-2012)
——————————————————————
since 1990 – Death rates from breast cancer steadily decreased in women (2009-2010)
since 1990 – death rate from breast cancer in women decreased (2007-2008)
——————————————————————
1.9% – 2000-2009 cancer mortality rate for women of all races combined declined annually (2012-2013)
——————————————————————
1990-2006 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
2.2% – 1990-2004 cancer mortality rate for women of all races combined decreased annually (2007-2008)
decline larger among younger age groups (2007-2008)
——————————————————————
2.3% – 1990-2002 rate decreased annually – percentage of decline larger among younger age groups (2005-2006)
——————————————————————
2.3% – 1990-2000 breast cancer death rates decreased annually (2005-2006)
——————————————————————
1992-1998 – mortality rates declined significantly
largest decreases in younger women, both white and black (2002)
——————————————————————
1.6% – 1975-1991 – Breast Cancer Death Rates Increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 – breast cancer death rates increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 death rate for all races combined increased annually (2005-2008)
——————————————————————
rate for women of all races combined decreased annually (2007-2008)
decline larger among younger age groups (2007-2008)
——————————————————————
BREAST CANCER – OLDER WOMEN
——————————————————————
Older women much more likely to get breast cancer than younger women
——————————————————————
% FEMALE BREAST CANCER DEATH RATES (age)
——————————————————————
97% – 1998-2002 – age 40 and older (2005-2008)
96% – 1996-2000 – age 40 and older (2005-2006)
——————————————————————
WOMEN YOUNGER than 50
——————————————————————
3.0% – under age of 50 – Mortality from breast cancer declined faster for women (annually from 2005-2009) regardless of race/ethnicity (2013)
——————————————————————
2.3% – 1990-2001 Breast Cancer Death Rates decrease
largest decrease in < 50 (2005-2006)
——————————————————————
3.7% – 1991-2000 under 50 breast cancer Death rates decreased (2005-2006)
——————————————————————
3.3% – 1990-2004 – death rates decreased per year among women younger than 50 (2005c-2008)
——————————————————————
2.3% – 1990-2002 Death rates from breast cancer declined average per year in all women combined, with larger decreases in younger (<50 years) women (2006)
——————————————————————
WOMEN 50 and older
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
——————————————————————
2.0% – 50 and older – 1990-2004 – death rates decreased per year among women (2005-2008)
——————————————————————
WHITE WOMEN
——————————————————————
2.1% – 2000-2009 – breast cancer death rates declined per year in white women
——————————————————————
2.6% – 1992-2000 – breast cancer Death rates Whites (2005-2006)
——————————————————————
2.4% – 1990-2004 female breast cancer death rates declined per year in whites (2005-2008)
——————————————————————
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – ALL CANCERS
——————————————————————
1.5% – since 1999 – Death rates among women (African Americans for all cancers combined) per year have been decreasing (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATHS
——————————————————————
black women more likely to die of breast cancer than white women (2012-2013)
——————————————————————
2005-2006 African American women more likely to die from breast cancer at every age
——————————————————————
41% – 2005-2009 African American women had higher death rate than white women despite lower incidence rate
39% – 2003-2007 – African American women had higher death rate than white women, despite lower incidence rate (2011-2012)
difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2011-2012)
37% – 2001-2005 – African American women had higher death rate than white women (2009-2010)
higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2009-2010)
difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2009-2010)
higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2007)
notable, striking divergence in long-term breast cancer mortality rates trends between African American and white women (2005-2008)
36% – by 2004 – death rates higher in African Americans than white women (2007-2008)
37% – by 2002 – death rates higher in African American women than white women (2005-2006)
36% – 2000-2003 – death rates higher in African American women than white women (2007)
difference accounts for one-third of excess cancer mortality experienced by African American women compared to white women (2007)
32% – 2000 – Breast Cancer Death rate higher in African American women even though had lower incidence rates (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – 50 and older
——————————————————————
1.2% – 50 and older – 1992-2012 – per year – women (2011-2012)
2.0% – 50 and older – Breast Cancer Death Rates – per year (2009-2010)
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
1.1% – 50 and older – 1991-2007 – African American women Breast cancer death rates declined annually (2007)
2.0% – 50 and older – 1990-2000 – breast cancer Death rates decreased (2005-2006)
——————————————————————
1990 – 50 and older – Breast Cancer Death Rates Increase predominantly due to
——————————————————————
AFRICAN AMERICAN WOMEN – under 50
——————————————————————
2.0% – 1992-2012 – decrease larger in women under 50 – declined thereafter per year (2011-2012)
1.9% – 1992-2009 – decrease larger in women under 50 – declined thereafter per year (2009-2010)
resulted in growing disparity
3.3% per year – larger decreases in women younger than 50 – Breast Cancer Death Rates (2009-2010)
——————————————————————
1.9% – 1991_-_2007 – decrease larger in women under 50 – African American women Breast cancer death rates declined annually per year
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
2000-2009 – death among females, rate of decline similar
As result, overall racial disparity narrowed
——————————————————————
2000-2009 death rate declined faster among African Americans females rate of decline than whites
1.5% – 2000-2009 African Americans females rate of decline per year (2013-2014)
1.4% – 2000-2009 whites rate of decline per year (2013-2014 )
——————————————————————
1.4% – 2000-2009 – breast cancer death rates declined more slowly per year in African American women
——————————————————————
1990-2002
African American women benefited less than white women from advances (2005-2008)
——————————————————————
1.1% – breast cancer death rates African Americans (2005-2006)
——————————————————————
1.6% – 1995-2004 – female breast cancer death rates declined per year in African Americans (2007-2008)
1.0% – 1990-2002 female breast cancer death rates declined per year – African Americans (2005-2006)
——————————————————————
early 1990s – Death rates among African Americans for all cancers combined have been decreasing (2011-2012)
——————————————————————
breast cancer death rates have declined more slowly in African American women compared to white women, which has resulted in growing disparity (2011-2012)
——————————————————————
gap much smaller among women
racial difference in overall cancer death rates due largely to cancers of breast and colorectum in women
racial disparity has widened for breast cancer in women (2011-2012)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women began in (2007-2008)
——————————————————————
early 1980s – breast cancer death rates for white and African American women approximately equal (2007)
——————————————————————
30% – early 1980’s-2000 – disparity between African American and white Deaths (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
early 1980s – breast cancer death rates for white and African American women
similar (2011-2014)
equal (2009-2010)
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
1.5% – 1975-1992 – Breast cancer death rates among African American women increased annually (2009-2012)
1.6% – 1975-1991 – African American women Breast cancer death rates increased annually (2007)
——————————————————————
1975-2007 – death rates for all cancers combined continued to be substantially higher among African Americans than whites (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATH RATE RATIOS per 100,000 women
——————————————————————
35.4 – African American – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
26.4 – White – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
1.3 – African American / White Ratio – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
——————————————————————
HISPANIC / LATINA WOMEN
——————————————————————
2.4% – 1995-2004 female breast cancer death rates declined per year in Hispanics / Latinas (2007-2008)
1.8% – 1990-2002 female breast cancer death rates declined per year in Hispanics / Latinas (2005-2006)
1.4% – breast cancer Death rates Hispanics (2005-2006)
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
ASIAN AMERICAN / PACIFIC ISLANDER WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among Asian Americans/Pacific Islanders (2007-2008)
1.1% – breast cancer Death rates Asian and Pacific Islanders (2005-2006)
1.0% – 1990-2002 female breast cancer death rates declined per year – Asian Americans / Pacific Islanders (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
AMERICAN INDIAN / ALASKA NATIVE WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among American Indians / Alaska Natives (2007-2008)
1990-2002 female breast cancer death rates did not decline in American Indian / Alaska Natives (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
breast cancer Death rates American Indian and Alaska Native – constant (2005-2006)
——————————————————————
DEATHS – 2007-2008
——————————————————————
40,460 – Deaths – All ages (2007-2008)
23,510 – Deaths – 65 and older (2007-2008)
16,950 – Deaths – Younger than 65 (2007-2008)
31,320 – Deaths – 55 and older (2007-2008)
9,140 – Deaths – Younger than 55 (2007-2008)
37,630 – Deaths – 45 and older (2007-2008)
2,830 – Deaths – Younger than 45 (2007-2008)
——————————————————————
MORTALITY (DEATH) RATES
——————————————————————
31.0 – Black – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
24.3 – White – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
14.8 – Hispanic – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
12.4 – American Indian / Alaskan Native – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
11.0 – Asian / Pacific Islander – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
WHITE WOMEN – MORE LIKELY TO DEVELOP BREAST CANCER
——————————————————————
Combining all age groups, white (non-Hispanic) women more likely to develop breast cancer than black women
——————————————————————
PROBABILITY of DEVELOPING BREAST CANCER in NEXT 10 YEARS (Age)
——————————————————————
20
——————————————————————
20 – 0.05% – 1 in 2,152 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
20 – 0.05% – 1 in 1,985 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
20 – 0.05% – 1 in: 1,837 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30
——————————————————————
30 – 0.44% – 1 in: 229 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
30 – 0.43% – 1 in: 234 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30 – 0.40% – 1 in 251 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40
——————————————————————
40 – 1.46% – 1 in: 68 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
40 – 1.45% – 1 in 69 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40 – 1.43% – 1 in: 70 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
50
——————————————————————
50 – 2.78% – 1 in 36 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
50 – 2.73% – 1 in: 37 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
50 – 2.51% – 1 in: 40 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
60
——————————————————————
60 – 3.82% – 1 in: 26 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
60 – 3.81% – 1 in 26 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
60 – 3.51% – 1 in: 28 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
70
——————————————————————
70 – 4.31% – 1 in 23 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
70 – 4.14% – 1 in: 24 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
70 – 3.88% – 1 in: 26 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
LIFETIME RISK
——————————————————————
13.2% – 1 in 8 – 2005-2006 Currently, woman living in US has, or, lifetime risk of developing breast cancer
——————————————————————
13.22% – Lifetime risk – 1 in: 8 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
12.28% – Lifetime risk – 1 in: 8 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
AFRICAN AMERICAN LIFE EXPECTANCY
——————————————————————
2007 – life expectancy lower for African Americans than whites among women
(76.5 vs. 80.6 years) (2011-2012)
——————————————————————
DEVELOPING INVASIVE BREAST CANCER
——————————————————————
1 in 8 – 2013 – chance of developing invasive breast cancer during lifetime
——————————————————————
1 in 8 – 12.3% – Currently, woman living in US has lifetime risk of developing breast cancer (2007-2008)
——————————————————————
about 1 in 11 – 1975
——————————————————————
1 in 11 – 1970s – lifetime risk of being diagnosed with breast cancer (2007-2008)
——————————————————————
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2005-2006)
——————————————————————
INVASIVE BREAST CANCER – by age (2007-2008)
——————————————————————
178,480 – All ages
72,520 – 65 and older
105,960 – Younger than 65
124,300 – 55 and older
54,180 – Younger than 55
162,330 – 45 and older
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER – by # (2007-2008)
——————————————————————
178,480 – All ages
162,330 – 45 and older
124,300 – 55 and older
105,960 – Younger than 65
72,520 – 65 and older
54,180 – Younger than 55
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER
——————————————————————
0.3% – 1987-2002 – Incidence Trends: increased per year (2005-2006)
————————————-
—————————–
4% (almost) – 1980-1987 – increased (almost +4% a year) Incidence Trends (2005-2006)
——————————————————————
age 40-49
——————————————————————
Since 1987 – age 40-49 – incidence rates of invasive breast cancer have slightly declined (2005-2006)
3.5% – 40-49 (age) – 1980-1987 – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
age 50 and older
——————————————————————
Since 1987 – 50 and older – incidence rates of invasive breast cancer have continued to increase among women, though at much slower rate (2005-2006)
4.2% – 50 and older – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
Under 40
——————————————————————
Under 40 – remained essentially constant (2005-2006)
Since 1987 – younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
——————————————————————
Invasive Breast Cancer
——————————————————————
1975-2000 – Invasive Breast Cancer (2005-2006):
4% – 40 and older – increased 1980-1987 then stabilized (2005-2006)
——————————————————————
1992-2002 – overall incidence rates did not change significantly among whites, African Americans, and Hispanics / Latinas (2005-2006)
——————————————————————
1.3% – Hispanics – increased overall (2005-2006)
——————————————————————
0.9% – Whites – increased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
Asian Americans / Pacific Islanders
——————————————————————
2.1% – 1992-2002 – Asian and Pacific Islanders – overall incidence rates increased overall (2005-2006)
1.5% – 1992-2002 – Asian Americans / Pacific Islanders – overall incidence rates increased per year (2005-2006)
trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
American Indian / Alaska Natives
——————————————————————
3.7% – American Indian / Alaska Native – decreased overall (2005-2006)
3.5% – 1992-2002 – American Indian / Alaska Natives – overall incidence rates decreased per year (2005-2006)
trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
essentially constant – Incidence Trends
——————————————————————
1973-1980 – essentially constant – Incidence Trends (2005-2006)
——————————————————————
African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective (2013-2014)
——————————————————————
MEDIAN AGE of DIAGNOSIS
——————————————————————
62 – median age of diagnosis for -white women
——————————————————————
57 – median age of diagnosis for African American women
——————————————————————
DIAGNOSIS at LOCAL STAGE
——————————————————————
61% – breast cancers diagnosed among white women at local stage (2011-2012)
——————————————————————
51% (Only about half) – of breast cancers diagnosed among African American women are local stage (2011-2014)
——————————————————————
MEDIAN AGE AT TIME OF BREAST CANCER DIAGNOSIS
——————————————————————
61 – 2000_-_2004 median age at time of breast cancer diagnosis (2007-2008)
61 – 1998_-_2002 median age at time of breast cancer diagnosis
——————————————————————
61 – means 50% of women who developed breast cancer were 61 or younger (2007-2008)
50% of women who developed breast cancer were age 61 or younger 1998_-_2002
——————————————————————
61 – 50% were older than 61 when diagnosed (2007-2008)
50% were older than age 61 when diagnosed 1998_-_2002
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER
——————————————————————
61 – median age for breast cancer diagnosis
0.0% – under age 20
1.8% – between 20-34
9.9% – between 35-44
22.5% – between 45-54
24.8% – between 55-64
20.2% – between 65-74
15.1% – between 75-84
5.7% – 85+
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER by % (SEER, 2012)
——————————————————————
24.8% – between 55-64
22.5% – between 45-54
20.2% – between 65-74
15.1% – between 75-84
9.9% – between 35-44
5.7% – 85+
1.8% – between 20-34
0.0% – under age 20
——————————————————————
IN SITU BREAST CANCER – by age (2007-2008)
——————————————————————
62,030 – All ages
21,510 – 65 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
54,390 – 45 and older
7,640 – Younger than 45
——————————————————————
IN SITU BREAST CANCER – by # (2007-2008)
——————————————————————
62,030 – All ages
54,390 – 45 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
21,510 – 65 and older
7,640 – Younger than 45
——————————————————————
NEW CASES – IN SITU BREAST CANCER
——————————————————————
increase observed in all age groups, although greatest in women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer leveled off among women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer have continued to increase in younger women (2007-2008)
——————————————————————
80% – 2000-2004 – Most in situ breast cancers are ductal carcinoma (DCIS), which accounted for about 80% of in situ breast cancers diagnosed (2007-2008)
——————————————————————
2000-2004 – Lobular carcinoma in situ (LCIS) less common than DCIS, accounting for about 10% of female in situ breast cancers diagnosed (2007-2008)
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer (2007-2008)
increase limited to women older than age 40 and largely to postmenopausal women (2007-2008)
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
12% – Lobular carcinoma in situ (LCIS) less common than DCIS
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer
increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1980s and 1990s – Incidence rates of in situ breast cancer increased rapidly (2007-2008)
——————————————————————
New cancer cases in women expected to be newly diagnosed among African Americans:
——————————————————————
2013 – 82,080 (About)
——————————————————————
19% – breast cancer in women (2007-2008)
——————————————————————
2002 – Breast cancer ranks 2nd among cancer deaths in women
——————————————————————
2002-2003: 2nd leading cause of death
——————————————————————
African American women expected to die from cancer:
——————————————————————
African Americans have the highest death rate and shortest survival of any racial and ethnic group in the US for most cancers
(2007-2014)
African Americans have the highest mortality rate of any racial and ethnic group in the US for most cancers
(2005-2006)
——————————————————————
higher death rate in African
American women compared to white women occurs despite lower cancer incidence rate (2013-2014)
——————————————————————
African American women have higher death rates overall and for breast and several other cancer sites (2013-2014)
——————————————————————
15% – 2009 – death rate for all cancers combined continued to be higher in African American women than in white women (2013-2014)
——————————————————————
racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women (2013-2014)
——————————————————————
overall racial disparity in cancer death rates decreasing (2013-2014)
——————————————————————
16% – 2007 – death rate for all cancers combined higher in African American women than white women (2011-2012)
——————————————————————
37% – by 2002 – death rates higher in African Americans than white women (2005-2006)
——————————————————————
since early 1990s – death rates among African Americans for all cancers combined have been decreasing (2013-2014)
——————————————————————
30% – early 1980’s–2000 – Deaths disparity between African American and white (2005–2006)
——————————————————————
1975-2009 – Despite declines, death rates for all cancers combined continued to be higher among African Americans than whites (2013-2014)
——————————————————————
1992-2014 – Breast cancer death rates among African American women declined
——————————————————————
1.4% per year – 2000-2009 – breast cancer death rates declined more slowly in African American women
——————————————————————
2.1% per year – 2000-2009 – breast cancer death rates declined white women
——————————————————————
early 1980s – breast cancer death rates for white and African American women similar
——————————————————————
1975-1992 – Breast cancer death rates among African American women increased
resulted in growing disparity
——————————————————————
through 1998 – breast cancer incidence rates among young white women continued to increase more slowly (2002)
——————————————————————
1980s – 4.5% per year increase (2002)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
1992-1998 – mortality rates declined significantly – largest decreases in younger women, both white and black (2002)
——————————————————————
1992-1998 – Incidence and Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
Incidence
——————————————————————
115.5 – White
101.5 – Black
78.1 – Asian / Pacific Islander
50.5 – American Indian / Alaskan Native
68.5 – Hispanic
——————————————————————
Mortality
——————————————————————
31.0 – Black
24.3 – White
14.8 – Hispanic
12.4 – American Indian / Alaskan Native
11.0 – Asian / Pacific Islander
——————————————————————
Cancer Facts & Figures for African Americans 2005-2006
——————————————————————
1995-2000 (2001) – Diagnosed
Female breast (2005-2006):
——————————————————————
Localized
——————————————————————
64% – White (2005-2006)
53% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
35% – African American (2005-2006)
28% – White (2005-2006)
——————————————————————
Distant
——————————————————————
9% – African American (2005-2006)
5% – White (2005-2006)
——————————————————————
Unstaged
——————————————————————
3% – African American (2005-2006)
2% – White (2005-2006)
——————————————————————
2005-2006 – Cancer Incidence Rates Ratios per 100,000 (1975-2001)
——————————————————————
1997-2001 – Breast (2005-2006)
143.2 – White (2005-2006)
118.6 – African American (2005-2006)
0.8 – African American / White Ratio (2005-2006)
——————————————————————
2005-2006 – Cancer Death Rate Ratios per 100,000
——————————————————————
1997-2001 – Breast (2005-2006)
35.4 – African American (2005-2006)
26.4 – White (2005-2006)
1.3 – African American / White Ratio (2005-2006)
——————————————————————
Most common cancer among African American Women (2005-2006)
——————————————————————
17% lower incidence rate in African American than White (2005-2006)
——————————————————————
under 40 – higher incidence rate in African American than White (2005-2006)
——————————————————————
25 years incidence:
——————————————————————
1999-2001 – leveling off (2005-2006)
1986-1999 – less rapid increase (2005-2006)
1978-1986 – rapid increase (2005-2006)
1975-1978 – stable (2005-2006)
——————————————————————
Breast Cancer Death Rates Increased (2005-2006):
——————————————————————
1975-1991 – + 1.6% – annually (2005-2006)
——————————————————————
1991 – decided annually: particularly in women younger than 50 (2005-2006)
——————————————————————
Breast Cancer Death Rates (2005-2006):
——————————————————————
early 1980’s – equal – African American / White (2005-2006)
——————————————————————
2000 – 32% – higher African American (2005-2006)
——————————————————————
Death rate higher in African American even though had lower incidence rates (2005-2006)
——————————————————————
Rate per 100,000
——————————————————————
White
African American
Asian or Pacific Islander
Hispanic
American Indian or Alaska Native
——————————————————————
1996-2000 – Incidences:
140.8 – White
121.7 – African American
97.2 – Asian or Pacific Islander
89.8 – Hispanic
58 – American Indian or Alaska Native
——————————————————————
1996-2000 – Deaths
35.9 – African American
27.2 – White
17.9 – Hispanic
14.9 – American Indian or Alaska Native
12.5 – Asian or Pacific Islander
——————————————————————
Estimated New In Situ Cases:
——————————————————————
2003_-_100 – < 30
2005 – 1,600 – Under 40
2003 – 2,100 – 30-39
2005 – 56,890 – 40 and older
2005 – 13,760 – Under 50
2003 -12,600 – 40-49
2005 – 44,730 – 50 and older
2005 – 37,040 – Under 65
2003 – 15,700 – 50-59
2005 – 21,450 – 65 and older
2003 – 11,500 – 60-69
2003 – 10,100 – 70-79
2003 – 3,500 – 80 +
2005 – 58,490 – All ages
TOTAL
2003 – 55,700
——————————————————————
2003_-_100 – 0.2%
2003 – 2,100 – 3.8%
2003 – 12,600 – 22.6%
2003 – 15,700 – 28.2%
2003 – 11,500 – 20.6%
2003 – 10,100 – 18.1%
2003 – 3,500 – 16.3
TOTAL
2003 – 100.0%
——————————————————————
Estimated New Invasive Cases:
——————————————————————
2003 – 1,000 – < 30
2005 – 9,510 – Under 40
2003 – 10,500 – 30-39
2005_-_201,730 – 40 and older
2005 – 45,780 – Under 50
2003 – 35,500 – 40-49
2005_-_165,460 – 50 and older
2005_-_123,070 – Under 65
2003 – 48,700 – 50-59
2005 – 88,170 – 65 and older
2003 – 43,100 – 60-69
2003 – 45,600 – 70-79
2003 – 27,000 – 80 +
2005_-_211,240 – All ages
TOTAL
2003 – 55,700 –
——————————————————————
2003 – 1,000 – 0.5%
2003 – 10,500 – 5.0%
2003 – 35,500 – 16.8%
2003 – 48,700 – 23.0%
2003 – 43,100 – 20.4%
2003 – 45,600 – 21.6%
2003 – 27,000 – 12.8%
TOTAL
2003 – 100.00%
——————————————————————
Deaths:
——————————————————————
2003_-_100 – < 30
2005 – 1,110 – Under 40
2003 – 1,300 – 30-39
2005 – 39,300 – 40 and older
2005 – 5,590 – Under 50
2003 – 4,300 – 40-49
2005 – 34,820 – 50 and older
2005 – 17,470 – Under 65
2003 – 7,000 – 50-59
2005 – 22,940 – 65 and older
2003 – 7,400 – 60-69
2003 – 9,500 – 70-79
2003 – 10,100 – 80 +
2005 – 40,410 – All ages
TOTAL
2003 – 39,800
——————————————————————
2003_-_100 – 0.3%
2003 – 1,300 – 3.3%
2003 – 4,300 – 10.8%
2003 – 7,000 – 17.6 %
2003 – 7,400 – 18.6%
2003 – 9,500 – 23.9%
2003 – 10,100 – 25.4%
TOTAL
2003 – 100.0
——————————————————————
1990 – Increase since predominantly due to women 50 and older
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
——————————————————————
12% – Lobular carcinoma in situ (LCIS) less common than DCIS
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer
increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1990-2001 (2005-2006):
——————————————————————
2.3% – decrease
largest decrease in < 50
——————————————————————
1998-2002 women aged 40 and older (2005-2006):
——————————————————————
95% – new cases
97% – breast cancer deaths
——————————————————————
1996-2000 Women 40 and older (2005-2006):
——————————————————————
94% – New Cases
96% – Deaths
——————————————————————
0.3% per year – Incidence rates declined slightly among white females (2013-2014)
——————————————————————
1996-2002 (2005-2006):
——————————————————————
20-24 – 1.3 per 100,000 lowest incidence rate – 1998-2002 (2005-2006)
20-24 – 1.4 per 100,000 lowest incidence rate – 1996-2000 (2005-2006)
——————————————————————
75-79 – 496.6 per 100,000 highest incidence rate – 1998-2002 (2005-2006)
75-79 – 499.0 per 100,000 highest incidence rate – 1996-2000 (2005-2006)
——————————————————————
2005-2006
•
White women higher incidence of breast cancer than African American women after 35
African American women slightly higher incidence rate before 35
African American women more likely to die from breast cancer at every age
——————————————————————
2005
White – higher incidence rate than African American women after 40
African American – slightly higher incidence rate before 40
African American women – more likely to die from at any age
——————————————————————
2005-2006 incidence and death rates from breast cancer lower among women of other racial and ethnic groups than white and African American women
——————————————————————
2000-2009 – stable among African American females (2013-2014)
——————————————————————
1975-1980 essentially constant (2005-2006)
1980-1987 + almost 4% per year (2005-2006)
1987-2002 + 0.3% per year (2005-2006)
•
Incidence Trends
Invasive Breast Cancer (2005-2006):
1973-1980 – essentially constant (2005-2006)
1980-1987 – + almost 4% year (2005-2006)
1987-2000 – 0.4% year (2005-2006)
——————————————————————
1980-1987 incidence rates of invasive breast cancer increased among women (2005-2006):
——————————————————————
40-49 (3.5% per year) (2005-2006)
50 and older (4.2% per year) (2005-2006)
Since 1987
50 and older – rates have continued to increase among women , though at much slower rate (2005-2006)
40-49 -rates have slightly declined (2005-2006)
younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
1975-2000 – Invasive Breast Cancer (2005-2006):
4% – 40 and older increased 1980 – 1987 then stabilized (2005-2006)
Under 40 – remained essentially constant (2005-2006)
——————————————————————
2005-2006 trends in invasive female breast cancer incidence rates:
——————————————————————
1992-2002
(1.5% per year) – overall incidence rates increased in Asian Americans / Pacific Islanders (2005-2006)
(3.5% per year) – decreased in American Indian/Alaska Natives (2005-2006)
did not change significantly among whites, African Americans, and Hispanics/Latinas (2005-2006)
1992-2000 – Invasive (2005-2006):
2.1% – Asian and Pacific Islanders – increased overall (2005-2006)
1.3% – Hispanics – increased overall (2005-2006)
0.9% – Whites – increased overall (2005-2006)
3.7% – American Indian and Alaska Native – decreased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
since 1990 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
1975-1990
0.4% – death rate for all races combined increased annually (2005-2006)
•
1990-2002
2.3% – rate decreased annually
percentage of decline larger among younger age groups (2005-2006)
1990-2002
3.3% – death rates decreased per year among women younger than 50 (2005-2006)
2.0% – per year among women 50 and older (2005-2006)
African American women and women of other racial and ethnic groups have benefited less than white women from advances (2005-2006)
1990-2002 female breast cancer death rates declined (2005-2006):
2.4% – per year – whites (2005-2006)
1.8% – per year – Hispanics/Latinas (2005-2006)
1.0% – per year – African Americans and Asian Americans/Pacific Islanders (2005-2006)
did not decline in American Indian/ Alaska Natives (2005-2006)
——————————————————————
life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years) (2013-2014)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
striking divergence in long-term mortality trends between African American and white females (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
1975-1990 – Death (2005-2006):
0.4% – increased annually (2005-2006)
——————————————————————
1990-2000
2.3% – decreased annually (2005-2006)
——————————————————————
1991-2000
3.7% – under 50 decreased (2005-2006)
——————————————————————
1990-2000
2.0% – 50 and older decreased (2005-2006)
——————————————————————
1992-2000 – Death (2005-2006):
——————————————————————
2.6% – Whites (2005-2006)
1.4% – Hispanics (2005-2006)
1.1% – African Americans (2005-2006)
1.1% – Asian and Pacific Islanders (2005-2006)
American Indian and Alaska Native – constant (2005-2006)
——————————————————————
Probability of developing Breast Cancer in next 10 years:
——————————————————————
Age
——————————————————————
20 – 0.05% – 1 in 2,152 (2005-2006)
20 – 0.05% – 1 in 1,985 – 2000-2002 (2005-2006)†
——————————————————————
30 – 0.40% – 1 in 251 (2005-2006)
30 – 0.44% – 1 in: 229 – 2000-2002 (2005-2006)†
——————————————————————
40 – 1.45% – 1 in 69 (2005-2006)
40 – 1.46% – 1 in: 68 – 2000-2002 (2005-2006)†
——————————————————————
50 – 2.78% – 1 in 36 (2005-2006)
50 – 2.73% – 1 in: 37 – 2000-2002 (2005-2006)†
——————————————————————
60 – 3.81% – 1 in 26 (2005-2006)
60 – 3.82% – 1 in: 26 – 2000-2002 (2005-2006)†
——————————————————————
70 – 4.31% – 1 in 23 (2005-2006)
70 – 4.14% – 1 in: 24 – 2000-2002 (2005-2006)†
——————————————————————
Lifetime Probability (%) of Developing or Dying from Invasive Cancers by Race and Sex
——————————————————————
Developing
12.73 (1 in 8) – White (%) 2007-2009 (2013-2014)
10.87 (1 in 9) – African American (%) 2007-2009 (2013-2014)
Dying
3.25 (1 in 31) – African American (%) 2007-2009 (2013-2014)
2.73 (1 in 37) – White (%) 2007-2009 (2013-2014)
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
13.22% – Lifetime risk – 1 in: 8
Comparison of Cancer Incidence Rates between African Americans and Whites
——————————————————————
123.2 – White Rate* 2005-2009 (2013-2014)
121.7 – White Rate* 2003-2007 (2011-2012)
130.6 – White Rate* 2001-2005 +
——————————————————————
118.1 – African American Rate* 2005-2009 (2013-2014)
114.7 – African American Rate* 2003-2007 (2011-2012)
117.6 – African American Rate* 2001-2005 +
——————————————————————
-5.1 – Difference† 2005-2009 (2013-2014)
-7.0 – Absolute Difference† 2003-2007 (2011-2012)
-13.1 – Absolute Difference† 2001-2005 +
——————————————————————
0.96 – Rate Ratio‡ 2005-2009 (2013-2014)
0.94 – Rate Ratio‡ 2003-2007 (2011-2012)
0.90 – Rate Ratio‡ 2001-2005 +
*Rates per 100,000 age adjusted to 2000 US standard population
†Difference is rate in African Americans minus rate in whites
†Absolute difference is rate in African Americans minus rate in whites
‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites
‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places
+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Comparison of Cancer Death Rates between African Americans and Whites
——————————————————————
31.6 – African American Rate* 2005-2009
32.4 – African American Rate* 2003-2007 (2011-2012)
33.5 – African American Rate* 2001-2005 +
——————————————————————
22.4 – White Rate* 2005-2009
23.4 – White Rate* 2003-2007 (2011-2012)
24.4 – White Rate* 2001-2005 +
——————————————————————
9.2 – Difference† 2005-2009
9.0 – Absolute Difference† 2003-2007 (2011-2012)
9.1 – Absolute Difference† 2001-2005 +
——————————————————————
1.41 – Rate Ratio‡ 2005-2009
1.39 – Rate Ratio‡ 2003-2007 (2011-2012)
1.37 – Rate Ratio‡ 2001-2005 +
*Rates per 100,000 and age adjusted to 2000 US standard population
†Difference is rate in African Americans minus rate in whites
†Absolute difference is rate in African Americans minus rate in whites
‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites
‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places
+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Stage Distribution for Selected Cancers in African Americans and Whites
Stage Distribution African Americans and Whites
——————————————————————
Localized
——————————————————————
61% – White 2002-2008
61% – White 1999-2006
62% – White 1996-2004 +
——————————————————————
51% – African American 2002-2008
51% – African American 1999-2006
51% – African American 1996-2004 +
——————————————————————
Regional
38% – African American 2002-2008
39% – African American 1999-2006
37% – African American 1996-2004 +
——————————————————————
32% – White 2002-2008
32% – White 1999-2006
31% – White 1996-2004 +
——————————————————————
Distant
——————————————————————
8% – African American 2002-2008
8% – African American 1999-2006
10% – African American 1996-2004 +
——————————————————————
5% – White 2002-2008
5% – White 1999-2006
6% – White 1996-2004 +
——————————————————————
Unstaged
——————————————————————
3% – African American 2002-2008
3% – African American 1999-2006
3% – African American 1996-2004 +
——————————————————————
2% – White 2002-2008
2% – White 1999-2006
2% – White 1996-2004 +
——————————————————————
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Probability of Developing Invasive Cancers Over Selected Age Intervals among African Americans by Sex +
Probability of Developing Invasive Cancers:
——————————————————————
Birth to 39 (%):
——————————————————————
0.53 (1 in 189) 2003-2005 * +
0.44 (1 in 229) 1998–2000 (2004)
0.44 (1 in 228) 1997–1999 (2003)
0.44 (1 in 229) 1996–1997 (2002)
——————————————————————
40 to 59(%):
——————————————————————
3.56 (1 in 28) – 40 to 59(%) 2003-2005 * +
4.14 (1 in 24) 1998–2000 (2004)
4.17 (1 in 24) 1997–1999 (2003)
4.17 (1 in 24) 1996–1997 (2002)
2.96 (1 in 34) – 60 to 69 (%) 2003-2005 * +
——————————————————————
60 to 79 (%):
——————————————————————
7.53 (1 in 13) 1998–2000 (2004)
7.14 (1 in 14) 1997–1999 (2003)
7.14 (1 in 14) 1996–1997 (2002)
5.44 (1 in 18) – 70 and Older (%) 2003-2005 * +
——————————————————————
Birth to Death (%)
——————————————————————
9.91 (1 in 10) – Birth to Death (%) 2003-2005 * +
13.36 (1 in 7) 1998–2000 (2004)
13.3 (1 in 8) 1997–1999 (2003)
12.5 (1 in 8) 1996–1997 (2002)
*For people free of cancer at beginning of age interval
+ Source:
DevCan:
Probability of Developing or Dying of Cancer Software, Version 6.3.0. Statistical Research and Applications Branch, National Cancer Institute, 2008
——————————————————————
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
——————————————————————
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
5-YEAR SURVIVAL RATE – ALL
——————————————————————
Survival after diagnosis of breast cancer continues to decline after 5 years (2009-2010)
Survival after diagnosis of breast cancer continues to decline beyond 5 years (2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL LOWER
——————————————————————
5-year relative survival lower among women with more advanced stage at diagnosis (2007-2008)
5-year relative survival lower among women with more advanced stage of disease at diagnosis (2005-2006)
——————————————————————
2005-2006 African American women with breast cancer less likely than white women to survive 5 years:
——————————————————————
90% – white
76% – African American
——————————————————————
Likely to survive 5 years (2005-2006):
——————————————————————
88% – White
74% – African American
——————————————————————
5-YEAR SURVIVAL RATE – ALL STAGES – COMBINED
——————————————————————
89% – survival rate at 5 years for all stages combined (2009-2010)
——————————————————————
88% – all stages combined – 5 year
——————————————————————
77% – all stages combined – 10 year
——————————————————————
5-YEAR RELATIVE SURVIVAL RATE for ALL CANCERS COMBINED
——————————————————————
63% – 2004
62% – 2002-2003
——————————————————————
5-year Relative Survival Rates* for Cancers by Race and Stage
Five-year Relative Survival Rates* for Cancers by Race and Stage at Diagnosis
Five-Year Relative Survival Rates
5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975–2001 (2004)
——————————————————————
Localized
——————————————————————
99% – White 2002-2008 (2013-2014)
61% – White 1999-2006 (2011-2012)
99% – White 1996-2004 +
98% – White 1995–2000 (2005–2006)
——————————————————————
93% – African American 2002-2008 (2013-2014)
51% – African American 1999-2006 (2011-2012)
93% – African American 1996-2004 +
91% – African American 1995–2000 (2005–2006)
——————————————————————
Regional
——————————————————————
85% – White 2002-2008 (2013-2014)
32% – White 1999-2006 (2011-2012)
85% – White 1996-2004 +
82% – White 1995–2000 (2005–2006)
——————————————————————
73% – African American 2002-2008 (2013-2014)
39% – African American 1999-2006 (2011-2012)
72% – African American 1996-2004 +
68% – African American 1995–2000 (2005–2006)
——————————————————————
Distant
——————————————————————
25% – White 2002-2008 (2013-2014)
5% – White 1999-2006 (2011-2012)
29% – White 1996-2004 +
27% – White 1995–2000 (2005–2006)
——————————————————————
15% – African American 2002-2008 (2013-2014)
8% – African American 1999-2006 (2011-2012)
17% – African American 1996-2004 +
15% – African American 1995–2000 (2005–2006)
——————————————————————
All Stages
——————————————————————
90% – White 2002-2008 (2013-2014)
2% – White 1999-2006 (2011-2012)
90% – White 1996-2004 +
56% – White 1995–2000
(2005–2006)
——————————————————————
78% – African American 2002-2008 (2013-2014)
3% – African American 1999-2006 (2011-2012)
77% – African American 1996-2004 +
50% – African American 1995–2000 (2005-2006)
——————————————————————
*Survival rates based on patients diagnosed 2002-2008 followed through 2009
*Survival rates based on patients diagnosed 1999-2006 followed through 2007
Survival rates based on patients diagnosed 1996 – 2004 followed through 2005 +
Local:
invasive cancer confined entirely to organ of origin
Regional:
malignant cancer either
1) extended beyond limits of organ of origin directly into surrounding organs or tissues
2) involves regional lymph nodes by way of lymphatic system
3) both regional extension and involvement of regional lymph nodes
Distant:
malignant cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Considering all races, 5-year relative survival:
98% – localized disease
81% – regional disease
26% – distant-stage disease
Larger tumor size at diagnosis associated with decreased survival
among women of all races with regional disease, 5-year relative survival:
92% – tumors less than or equal to 2.0 cm
77% – tumors 2.1-5.0 cm
65% – tumors greater than 5.0 cm
——————————————————————
OVERALL 5-YEAR CANCER SURVIVAL RATE (2005-2006)
——————————————————————
55% – 1995-2000 (2005-2006)
27% – 1960-1963 (2005-2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL RATES
——————————————————————
89% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2007-2008)
88% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2005-2006)
87% – 5 year Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
age 75 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 75 and older (2005-2006)
86% – 75 and over (2005-2006)
——————————————————————
age 65 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
89% – 65-74 (2005-2006)
88% – 65 and over (2005-2006)
——————————————————————
5-year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 55-64 (2005-2006)
89% – 40-74 (2005-2006)
87% – 45-54 (2005-2006)
83% – 45 (less than) (2005-2006)
——————————————————————
40 and older – 5-year relative survival rate
——————————————————————
89% – 40 and older – 5-year relative survival rate slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
younger than 40 – 5-year relative survival rate
——————————————————————
82% – before 40 – slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
82% – younger than 40 – slightly lower among women diagnosed with breast cancer before age 40 – may be due to tumors in age group being more aggressive (2005-2006)
——————————————————————
All – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
86% – 1992-1997 (2002) – 1974-1997
78% – 1983-1985 (2002) – 1974-1997
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN
——————————————————————
69% – white women (2013-2014)
——————————————————————
62% – white women (2007)
——————————————————————
90% – 1999-2006 white women (2011-2012)
——————————————————————
90% – 1996-2004 white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – white women with breast cancer to survive 5 years (2007-2008)
——————————————————————
5-year survival greater among white women (2007)
——————————————————————
90% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among white women
——————————————————————
88% – White women – Likely to survive 5 years (2005-2006)
——————————————————————
81% – White women – 5 year survivors: relative 5 year survival rate (2005-2006)
——————————————————————
62% – 1996-2004 – white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – 1996-2002 – whites (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
90% – 1996-2002 – White – 5-Year Relative Survival – Breast 2007 (2007-2008) +
——————————————————————
89% – 1995-2000 – White – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004) (2005-2006)
——————————————————————
87% – 1992-1997 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
79% – 1983-1985 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
75% – 1974-1976 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
78% – black women still living 5 years after getting disease (SEER, 2012)
——————————————————————
78% – 1999-2006 – 5-year relative survival rate for breast cancer diagnosed among African American women Survival and Stage at Distribution (2011-2012)
——————————————————————
76% – African American – 5 year survivors relative 5 year survival rate (2005-2006)
——————————————————————
74% – African American – Likely to survive 5 years (2005-2006)
——————————————————————
60% – African Americans – continue to have lower 5-year survival than whites overall and for each stage of diagnosis for most cancer sites (2013-2014)
African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2009-2010)
Within each stage, 5-year survival also lower among African American women (2009-2010)
78% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among African American women
77% – African American women with breast cancer less likely than white women to survive 5 years (2007-2008)
76% – African American women with breast cancer less likely than white women to survive 5 years 2005-2006
60% – 2002-2008 – overall 5-year relative survival rate among African Americans improved (2013-2014)
59% – 1999-2006 – African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2011-2012)
58% – 1996-2004 – overall 5-year relative survival rate among African Americans improved (2009-2010)
77% – 1996-2002 – 5-Year Relative Survival – Breast – African American 2007 (2007-2008) +
77% – 1996-2002 – African American women (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
72% – 1992-1997 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
63% – 1983-1985 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
63% – 1974-1976 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
27% – 1960-1963 – overall 5-year relative survival rate among African Americans improved (2009-2014)
——————————————————————
1996-2002 – 5-Year Relative Survival – Breast 2007 – (Based on cancer patients diagnosed 1996-2002 followed through 2003) (2007-2008) +
(Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
——————————————————————
relative survival rates for women diagnosed with breast cancer (2005-2006):
•
88% – 5 years after diagnosis (2005-2006)
80% – 10 years (2005-2006)
71% – 15 years (2005-2006)
63% – 20 years (2005-2006)
•
Breast Cancer Survival Rates after Diagnosis:
•
87% – 5 years (2005-2006)
77% – 10 years (2005-2006)
63% – 15 years (2005-2006)
52% – 20 years (2005-2006)
——————————————————————
2005-2006 – 5-year relative survival rate slightly lower among women diagnosed with breast cancer before age 40
•
may be due to tumors in age group being more aggressive and less responsive to hormonal therapy:
•
82% – younger than 40 (2005-2006)
89% – 40 – 74 (2005-2006)
88% – 75 and older (2005-2006)
•
5 year relative survival rate (2005-2006):
•
83% – < 45
87% – 45 – 54
88% – 55 – 64
89% – 65 – 74
88% – 65 and over
86% – 75 and over
——————————————————————
5 year survivors
relative 5 year survival rate (2005-2006):
•
81% – White
76% – African American
——————————————————————
10 year survivors after diagnosis
relative 5 year survival rate (2005-2006):
——————————————————————
87% – White
85% – African American
——————————————————————
LOCALIZED CANCER INCIDENCE RATES RATIOS per 100,000 (1975-2001) – 1995-2000 (2001) – Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed 2005-2006
——————————————————————
143.2 – White
118.6 – African American
0.8 – African American / White Ratio
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004)
89% – White (2005-2006)
75% – African American (2005-2006)
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004)
Female breast
——————————————————————
Localized
——————————————————————
98% – White (2005-2006)
91% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
82% – White (2005-2006)
68% – African American (2005-2006)
——————————————————————
Distant
——————————————————————
27% – White (2005-2006)
15% – African American (2005-2006)
——————————————————————
Unstaged
——————————————————————
56% – White (2005-2006)
50% – African American (2005-2006)
——————————————————————
LOCALIZED 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
98% – 1995-2000 – White
91% – 1995-2000 – African American
——————————————————————
LOCALIZED
——————————————————————
98% – 2010 – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)
98% – localized disease: 5-year relative survival – Considering all races (2007-2008)
98% – 2006 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
98% – localized disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races
98% – 2005 – 5 year relative survival for localized
97% – 2004 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
96% – 2002 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
99% – 1996-2002 White – localized (2007-2008) *
94% – 1996-2002 African American – localized (2007-2008) *
80% – 1950s – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)
80% – 1950s – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2006)
72% – 1940s – 5-year relative survival rate for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2002)
——————————————————————
5-year relative survival rate for breast cancer diagnosed at local stage
——————————————————————
77% – 1996-2004 – African American women – 5-year relative survival rate for breast cancer diagnosed at local stage (2009-2010)
——————————————————————
LOCALIZED
——————————————————————
62% – 1996-2002 White – Localized – Stage Distribution – Female breast (2007-2008)
64% – White – Localized (2005–2006)
64% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
5% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
52% – 1996-2002 African American – Localized – Stage Distribution – Female breast (2007-2008)
53% – African American – Localized (2005–2006)
53% – 1995-2000 (2001) – African American: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
——————————————————————
REGIONAL 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
82% – 1995-2000 – White
68% – 1995-2000 – African American
——————————————————————
REGIONALLY
——————————————————————
84% – cancer spread regionally, current 5-year survival (2009-2010)
84% – regional disease – 5-year relative survival: Considering all races (2007-2008)
81% – regional disease – 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races 2005-2006
85% – 1996-2002 White – Regional (2007-2008) *
80% – cancer spread regionally
78% – 2002 – 5-year relative survival rate: breast cancer spread regionally
72% – 1996-2002 African American – Regional (2007-2008) *
——————————————————————
36% – 1996-2002 African American – Regional: Stage Distribution – Female breast (2007-2008)
30% – 1996-2002 White – Regional: Stage Distribution – Female breast (2007-2008)
35% – African American – Regional (2005–2006)
35% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Regional – Of all breast cancers diagnosed
28% – White – Regional (2005–2006)
——————————————————————
REGIONAL TUMORS
——————————————————————
94% – Larger tumor size at diagnosis also associated with decreased survival among women of all races with regional disease, 5-year relative survival for tumors less than or equal (2007-2008)
92% – tumors less than or equal to 2.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
77% – tumors 2.1-5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
65% – tumors greater than 5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
——————————————————————
DISTANT
——————————————————————
27% – women with distant spread (metastases) 5-year survival (2009-2010)
27% – 1995-2000 – White – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
27% – distant-stage disease: 5-year relative survival, Considering all races (2007-2008)
26% – distant metastasis
26% – distant-stage disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races
28% – 1996-2002 White – Distant (2007-2008) *
21% – 2002 – 5-year relative survival rate: breast cancer distant metastasis
16% – 1996-2002 African American – Distant (2007-2008) *
15% – 1995-2000 – African American – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
28% – 1995-2000 (2001) – White: Distant – Diagnosed Female breast (2005-2006): Of all breast cancers diagnosed
——————————————————————
9% – 1996-2002 African American – Distant – Stage Distribution African Americans – Female breast (2007-2008)
9% – African American – Distant (2005–2006)
9% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Localized – Of all breast cancers diagnosed
6% – 1996-2002 White – Distant – Stage Distribution Whites – Female breast (2007-2008)
5% – White – Distant (2005–2006)
——————————————————————
UNSTAGED
——————————————————————
56% – 1996-2002 – Unstaged – White (2007-2008) *
56% – 1995-2000 – White – Unstaged 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
50% – 1995-2000 – Unstaged – African American – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
45% – 1996-2002 – Unstaged – African American (2007-2008) *
——————————————————————
3% – 1996-2002 African American – Unstaged – Stage Distribution Whites – Female breast (2007-2008)
3% – African American – Unstaged (2005–2006)
3% – 1995-2000 (2001) – African American: Unstaged – Of all breast cancers diagnosed – Diagnosed
Female breast (2005-2006)
2% – 1996-2002 White – Unstaged – Stage Distribution Whites – Female breast (2007-2008)
2% – White – Unstaged (2005–2006)
2% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Unstaged – Of all breast cancers diagnosed
——————————————————————
ALL – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
90% – 1999-2006 (2011) – 1975-2006
87% – 1992-1999 (2004)
87% – 1992-1999 (2004) – 1974-1999
86% – 1974-1998 (2003)
86% – 1992-1998 (2003) – 1974-1998
86% – 1992-1997 (2002) – 1974-1997
79% – 1984-1986 (2011) – 1975-2006
78% – 1983-1985 (2004)
78% – 1983-1985 (2004) – 1974-1999
78% – 1983-1985 (2002) – 1974-1997
75% – 1975-1977 (2011) – 1975-2006
78% – 1974-1998 (2003)
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 (2011) – 1975-2006
90% – 1996-2002 (2007)
88% – 1992-1999 (2004)
88% – 1992-1999 (2004) – 1974-1999
88% – 1992-1998 (2003) – 1974-1998
88% – 1974-1998 (2003)
87% – 1992-1997 (2002) – 1974-1997
81% – 1984-1986 (2011) – 1975-2006
79% – 1983-1985 (2004)
79% – 1983-1985 (2004) – 1974-1999
79% – 1983-1985 (2002) – 1974-1997
76% – 1975-1977 (2011) – 1975-2006
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
AFRICAN AMERICAN WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
78% – 1999-2006 (2011) – 1975-2006
77% – 1996-2002 (2007)
74% – 1992-1999 (2004)
74% – 1992-1999 (2004) – 1974-1999
73% – 1992-1998 (2003) – 1974-1998
73% – 1974-1998 (2003)
72% – 1992-1997 (2002) – 1974-1997
65% – 1984-1986 (2011) – 1975-2006
64% – 1983-1985 (2004)
64% – 1983-1985 (2004) – 1974-1999
63% – 1983-1985 (2002) – 1974-1997
63% – 1974-1998 (2003)
63% – 1974-1976 (2004)
63% – 1974-1976 (2004) – 1974-1999
63% – 1974-1976 (2002) – 1974-1997
62% – 1975-1977 (2011) – 1975-2006
——————————————————————
COMBINED – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
90% – 1996-2002 – White Women (2007)
87% – 1992-1997 – White Women – 1974-1997 (2002)
86% – 1992-1997 – All – 1974-1997 (2002)
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
79% – 1983-1985 – White Women – 1974-1997 (2002)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
78% – 1983-1985 – All – 1974-1997 (2002)
77% – 1996-2002 – African American Women (2007)
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
75% – 1974-1976 – All – 1974-1997 (2002)
75% – 1974-1976 – White Women – 1974-1997 (2002)
72% – 1992-1997 – African American Women – 1974-1997 (2002)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
63% – 1983-1985 – African American Women – 1974-1997 (2002)
63% – 1974-1976 – African American Women – 1974-1997 (2002)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
COMBINED by YEAR – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
——————————————————————
90% – 1996-2002 – White Women (2007)
77% – 1996-2002 – African American Women (2007)
——————————————————————
87% – 1992-1997 – White Women (2002)
86% – 1992-1997 – All (2002)
72% – 1992-1997 – African American Women (2002)
——————————————————————
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
——————————————————————
79% – 1983-1985 – White Women (2002)
78% – 1983-1985 – All (2002)
63% – 1983-1985 – African American Women (2002)
——————————————————————
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
75% – 1974-1976 – All (2002)
75% – 1974-1976 – White Women (2002)
63% – 1974-1976 – African American Women (2002)
——————————————————————
Stages (%) – 5-Year Relative Survival Rates by Stage at Diagnosis
——————————————————————
97.0% – 1992-1999 – Local (2004)
97% – 1992-1998 – Local (2003)
96% – 1992-1997 – Local (2002)
——————————————————————
88% – 2006 – All Stages (2006)
86.6% – 1992-1999 – All Stages (2004)
86% – 1992-1998 – All Stages (2003)
86% – 1992-1997 – All Stages (2002)
——————————————————————
81% – Regional (2006)
78.7% – 1992-1999 – Regional (2004)
78% – 1992-1998 – Regional (2003)
78% – 1992-1997 – Regional (2002)
——————————————————————
26% – 2006 – distant metastases (2006)
23.3% – 1992-1999 – Distant (2004)
23% – 1992-1998 – Distant (2003)
21% – 1992-1997 – Distant metastases (2002)
——————————————————————
*
——————————————————————
1996-2002 – 5-Year Relative Survival Rates (5-year relative survival rate among cancer patients diagnosed 1996-2002 followed through 2003) *
Female breast – (Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
Local:
invasive cancer confined entirely to organ
Regional:
malignant cancer
1) extended beyond limits of organ of origin directly into surrounding organs or tissues
2) involves regional lymph nodes by way of lymphatic system
3) has both regional extension and involvement of regional lymph nodes
Distant:
cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes
Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006 (2007-2008)
——————————————————————
5-YEAR SURVIVAL – INVASIVE BREAST CANCER
——————————————————————
90% – 2002-2008 – women diagnosed with invasive breast cancer still living 5 years after getting disease (SEER, 2012)
——————————————————————
10-YEAR SURVIVAL RATES
——————————————————————
Caution should be used when interpreting 10-year survival rates since they represent detection and treatment circumstances 5-17 years ago and may underestimate expected survival based on current conditions (2009-2010)
Caution should be used when interpreting long-term survival rates since they reflect experience of women treated using past therapies and do not reflect recent trends in early detection or advances in treatment (2007-2008)
——————————————————————
87% – White – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
85% – African American – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
81% – 10 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
80% – 10 year – survival rate for all stages combined (2009-2010)
——————————————————————
80% – 10 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
77% – 10 year – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
15-YEAR SURVIVAL RATE
——————————————————————
73% – 15 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
71% – 15 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
63% – 15 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
20-YEAR SURVIVAL RATE
——————————————————————
63% – 20 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
52% – 20 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
======================================
Breast Cancer
American Cancer Society
Cancer Facts & Figures (2002-2014)
======================================
REFERENCES:
======================================
[A] – .7/30/2013, Tuesday – Karmanos Cancer Center’s Dr. David Gorski appointed program co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://www.karmanos.org/News/Default.aspx?sid=1&nid=359
======================================
[B] – .7/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://prognosis.med.wayne.edu/article/dr-gorski-named-codirector-of-michigan-breast-oncology-quality-initiative
======================================
[C] – 07/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative : ——————————————————————
http://www.wsupgdocs.org/news-and-media/WayneStateContentPage.aspx?nd=1293&news=515
======================================
[D] – 2/1/2011 – Barbara Ann Karmanos Cancer Center Names Dr. David Gorski Leader of Breast Multidisciplinary Team:
/PRNewswire-USNewswire/ — The Barbara Ann Karmanos Cancer Center has named David Gorski, M.D., Ph.D., leader of the Breast Multidisciplinary Team (MDT), effective Tuesday, Feb. 1
——————————————————————
http://m.prnewswire.com/news-releases/barbara-ann-karmanos-cancer-center-names-dr-david-gorski-leader-of-breast-multidisciplinary-team-115018114.html
======================================
[E] – 11/2/2011, Wednesday – Make the Right Move:
——————————————————————
http://www.karmanos.org/News/breast-cancer-specialists
======================================
[F]
——————————————————————
http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php
======================================
[G] – Research Interest:
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[H]
——————————————————————
http://wsusurgery.com/facultyc3/david-gorski/
——————————————————————
http://www.wsusurgery.com/facultyc3/david-gorski/
======================================
[I]
——————————————————————
http://wsusurgery.com/research-team-dr-gorski/
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[J]
——————————————————————
http://karmanos.org/Physicians/Details.aspx?sid=1&physician=70
——————————————————————
http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=70
======================================
[K]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/
======================================
[L]
——————————————————————
http://www.scienceinmedicine.org/fellows/GorskiD.html
——————————————————————
http://scienceinmedicine.org/fellows/GorskiD.html
======================================
[M]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
======================================
[N]
——————————————————————
http://scienceblogs.com/insolence
======================================
[O]
——————————————————————
http://ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
——————————————————————
http://www.ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
======================================
[P]
——————————————————————
http://whybiotech.com/?p=3808
——————————————————————
http://www.whybiotech.com/?p=3808
======================================
[Q]
——————————————————————
http://en.wikipedia.org/wiki/David_Gorski
======================================
[R] – Breast Cancer Research – Dr. Gorski:
——————————————————————
http://www.wsusurgery.com/breast-cancer-research-dr-gorski/
======================================
[S] – Selected Publications:
——————————————————————
http://www.wsusurgery.com/selected-publications-dr-gorski/
======================================
[T] – Lab Photos:
——————————————————————
http://www.wsusurgery.com/lab-photos-dr-gorski/
======================================
[U]
——————————————————————
https://www.doximity.com/pub/david-gorski-md
======================================
[V] – Detroit, Michigan population
——————————————————————
http://www.worldpopulationstatistics.com/detroit-population-2013/
======================================
[W]
——————————————————————
http://quickfacts.census.gov/qfd/states/26/2622000.html
======================================
[X]
——————————————————————
http://www.city-data.com/city/Detroit-Michigan.html
======================================
[Y] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[Z] – 3/9/2013 – Quackademic Medicine: How pseudoscience is infiltrating medical academia.”
——————————————————————
http://m.youtube.com/watch?v=mewOSMNgfGQ&desktop_uri=%2Fwatch%3Fv%3DmewOSMNgfGQ
======================================
[]
——————————————————————
http://www.nixonlibrary.gov/forresearchers/find/tapes/excerpts/watergate.php
——————————————————————
http://whitehousetapes.net/transcript/nixon/cancer-presidency
——————————————————————
http://m.washingtonpost.com/politics/cancer-on-the-presidency/2012/06/08/gJQAp24LOV_video.html
——————————————————————
http://www.history.com/speeches/nixon-and-dean-discuss-watergate
======================================
2013-2014 Breast Cancer Facts & Figures
——————————————————————
Click to access acspc-040951.pdf
——————————————————————
Click to access acspc-040951.pdf
——————————————————————
2013-2014 Cancer Facts & Figures for African Americans
——————————————————————
Click to access acspc-036921.pdf
——————————————————————
Click to access acspc-036921.pdf
——————————————————————
2012-2014 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————
Click to access acspc-034778.pdf
——————————————————————
Click to access acspc-034778.pdf
======================================
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
2013-2014 Cancer Facts & Figures
——————————————————————
Click to access acspc-040951.pdf
——————————————————————
Click to access acspc-040951.pdf
——————————————————————
——————————————————————
http://onlinelibrary.wiley.com/doi/10.3322/caac.21203/full
——————————————————————
2013
——————————————————————
Click to access breast-cancer-facts-2012.pdf
——————————————————————
Click to access breast-cancer-facts-2012.pdf
——————————————————————
2012-2013 Survivorship
——————————————————————
Click to access acspc-033876.pdf
——————————————————————
Click to access acspc-033876.pdf
——————————————————————
2013 – Cancer Facts & Figures
——————————————————————
Click to access acspc-036845.pdf
——————————————————————
Click to access acspc-036845.pdf
——————————————————————
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
======================================
2011-2012 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
Click to access acspc-031941.pdf
——————————————————————
Click to access acspc-031941.pdf
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
2011-2012 Cancer Facts & Figures for African Americans
——————————————————————
Click to access acspc-027765.pdf
——————————————————————
Click to access acspc-027765.pdf
======================================
2011 – Cancer Facts & Figures
——————————————————————
Click to access acspc-029771.pdf
——————————————————————
Click to access acspc-029771.pdf
——————————————————————
2011 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
2009-2011 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————
Click to access ffhispanicslatinos20092011.pdf
——————————————————————
Click to access ffhispanicslatinos20092011.pdf
======================================
2010
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
2009-2010 Breast Cancer Facts & Figures
——————————————————————
Click to access f861009final90809pdf.pdf
——————————————————————
Click to access f861009final90809pdf.pdf
——————————————————————
2010 – Cancer Facts & Figures
——————————————————————
Click to access acspc-024113.pdf
——————————————————————
Click to access acspc-024113.pdf
——————————————————————
2010 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————
Click to access cffaa20092010pdf.pdf
——————————————————————
Click to access cffaa20092010pdf.pdf
======================================
2009
——————————————————————
http://www.komenstlouis.org/site/DocServer/DiversityAsianPacific.pdf?docID=222
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————
Click to access cffaa20092010pdf.pdf
——————————————————————
Click to access cffaa20092010pdf.pdf
——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
Click to access 500809webpdf.pdf
——————————————————————
Click to access 500809webpdf.pdf
——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
======================================
Breast Cancer Facts & Figures
——————————————————————
http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
2007-2008 Breast Cancer Facts & Figures
——————————————————————
Click to access bcfffinalpdf.pdf
——————————————————————
Click to access bcfffinalpdf.pdf
——————————————————————
Cancer Facts and Statistics
——————————————————————
http://cancer.org/research/cancerfactsstatistics/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
Click to access 2008cafffinalsecuredpdf.pdf
——————————————————————
Click to access 2008cafffinalsecuredpdf.pdf
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
Click to access worldcancer.pdf
——————————————————————
Click to access worldcancer.pdf
——————————————————————
Global
——————————————————————
Click to access acspc-027766.pdf
——————————————————————
Click to access acspc-027766.pdf
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
======================================
2007-2008 Breast Cancer Facts & Figures
——————————————————————
Click to access bcfffinalpdf.pdf
——————————————————————
Click to access bcfffinalpdf.pdf
——————————————————————
——————————————————————
http://komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————
——————————————————————
http://ww5.komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
Click to access caff2007pwsecuredpdf.pdf
——————————————————————
Click to access caff2007pwsecuredpdf.pdf
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
2007-2008 Cancer Facts & Figures for African Americans
——————————————————————
Click to access caff2007aaacspdf2007pdf.pdf
——————————————————————
Click to access caff2007aaacspdf2007pdf.pdf
——————————————————————
2006-2008 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————
Click to access caff2006hisppwsecuredpdf.pdf
——————————————————————
Click to access caff2006hisppwsecuredpdf.pdf
======================================
2006 – Cancer Facts & Figures
——————————————————————
Click to access caff2006pwsecuredpdf.pdf
——————————————————————
Click to access caff2006pwsecuredpdf.pdf
——————————————————————
2006 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
Click to access caff2005brfacspdf2005pdf.pdf
——————————————————————
Click to access caff2005brfacspdf2005pdf.pdf
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Cancer Facts & Figures for African Americans
——————————————————————
Click to access caff2005aacorrpwsecuredpdf.pdf
——————————————————————
Click to access caff2005aacorrpwsecuredpdf.pdf
======================================
2005 – Cancer Facts & Figures
——————————————————————
Click to access caff2005f4pwsecuredpdf.pdf
——————————————————————
Click to access caff2005f4pwsecuredpdf.pdf
——————————————————————
——————————————————————
http://worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————
——————————————————————
http://www.worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2005 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
======================================
2003-2004 Breast Cancer Facts & Figures
——————————————————————
Click to access caff2003brfpwsecuredpdf.pdf
——————————————————————
Click to access caff2003brfpwsecuredpdf.pdf
——————————————————————
2004 – Cancer Facts & Figures
——————————————————————
Click to access CancerRates2004.pdf
======================================
2003
——————————————————————
http://cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
http://m.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
2003 – Cancer Facts & Figures
——————————————————————
Click to access 2003_ACS_Cancer_Facts.pdf
======================================
2002 – American Cancer Society Cancer Facts & Figures
——————————————————————
Click to access acspc-027766.pdf
——————————————————————
Click to access acspc-027766.pdf
——————————————————————
2002 – Cancer Facts & Figures
——————————————————————
Click to access CancerFacts&Figures2002.pdf
======================================
Pete Cohen chats with Dr. Stanislaw Burzynski – Interview #2
======================================
Dr. B interview #2
2/7/2013 (10:31)
======================================
Why do you continue to do this ?
Why haven’t you just, given up ?
Because I am right
Why should I stop when I have 100’s of people who are cured
Mhmm
from incurable brain tumors
Ok
We have over 100 people, who are surviving over 5 years, just in the supervised clinical trials with brain tumors
So obviously this works (laughing)
It works in great way
So why should I stop because, some evil people like me to stop ?
It doesn’t make any sense
Evil will lose
So we are right, and we’re going to win
Not, uh, no matter how soon this will be established, but we are going to win
Well, for what it’s worth, and this is something, this is why I wanted to put myself, uh, in front of the camera with you
Obviously I spent 8 months, um, and I’ll try and not get too emotional about it, because that’s unprofessional (laughs)
Yes
but I spent, I spent a long time, looking into this, speaking to people,
Yes
You have very kindly given me access to everything here
Sure
Speak to anyone
Speak to patients
To see medical records, and I have, uh, been amazed by what I, what I’ve seen
I know the statistics are now showing, in the world, that one in two men, will have cancer
One in 3 women, will have cancer
Yes
It’s a, it’s a massive problem
That’s right
And I can see that you’ve genuinely found, uh, a cure for cancer
(?)
You know, it might not work for everyone, but if you’re given the su
Yeah
given the support
Yes
If you’re given, uh, the, uh, I don’t know, just the support basically, and the funds maybe, you could really, do some work, that could change, the whole (nature ?)
Absolutely, and then we can get better, and better
Of course, what you have now is not yet the finished products
We understand that
That’s something we can substantially improve
The response rate can be improved
So, certainly, all of this can be done, but, obviously, we need the resources
We need time to do it, and most of my time is spent with such silly thing like, uh, uh, protecting ourselves against attacks from, the people who are hired to destroy us
Ok
Obviously, there are some companies who are working on the payroll of pharmaceutical business, who are trying to smear us
To spread bad publicity about us
To generate lies about us
These people are criminals, and they are still flourishing
The end for them will come soon, but they are still hurting the other people
because the other people will not take treatment
They will not come, and they will die
Ok
There is no cure for, uh, uh, malignant brain tumors which are inoperable, ok, and we can cure at least, good percent of these people
We presented, our results, at many, many, 1st class
scientific congresses, like nuero-oncology congresses, cancer congresses, and it’s important for U.K.
I showed you yesterday, eh, presentation on brainstem glioma in children
Yeah, I have it here
and at the same, uh, Congress, in Edinburgh, we presented also another, eh, eh, paper, on the treatment of glioblastoma multiforme, and the survival on, about 88 patients, in glioblastoma multiforme
So obviously, I make, I make this available to everybody , they would like to listen, come to my presentation
They, they, they know about it, but they don’t want to know about it
Why not ?
(laughs) Because they are working
They are slaves of the big pharmaceutical cartels, ok, and on the payroll of big companies
They hate to see somebody else outside, the slavery, who can do it
I’m free man
I can, ah, do the research because, I am spending my own money for it
I don’t need to beg pharmaceutical companies or government to give me the money
I can do it on my own
They hate it
These people
They hate it because they have slave mentality
Mmm
They arch their back for scraps of money from the table, of some powerful companies, from the government, and they, how can you deal with s, slaves
They don’t want to see something new because this would disrupt, slavery system
Ok
So, current medical education s, system is manufacturing robots
They don’t think on their own, they use only what, the government, or the lawyers of the government, or what the administrators will tell them to do, ok, and if they don’t then they get punished, ok (laughs), and that’s a great system for a ph, pharmaceutical companies, because obviously they can make a lot of money, but it’s not a great system for people who have cancer because they don’t have good results
So you’ve presented at these conferences, and people don’t come up to you afterwards and say:
Mhmm
“I want to come and see what you’re doing
I’ve got to see this for myself”
Ah, well, uh, at each of these Congresses I meet a few doctors who are top specialists in their area who will come to me and say: “Ok, this looks very interesting
We’d like to know more about it
Please send me some, eh, results and a few cases that I can review,” and that’s what you do
Yeah
You send them these cases, and that’s the end of it
I don’t hear from them anymore because they’re afraid to move any
Mmm
further, ok, because they know if they move further, they get punished
They don’t receive grants
They’d be scrutinized by their peers
They’re afraid
Ok (laughs)
Yeah
They work for us
Yeah
they work for us undercover
We have over 100 telephone callers who used to work with us, but they don’t want anybody to know about it because they’d be immediately attacked by the other guys
And the pharmaceutical world as well
Ah, well, the other guys are obviously working for cartels
Uh, they’re on the payroll, a, oh, of big business, which is cancer business, and they don’t want to lose it
Uh, in average, uh, city you might have say about 20 oncologists
One of them may work for us, but he does not no, want to tell anybody that he’s doing this because he would be destroyed by the other guys
These 20 guys will jump on him and he will, won’t have practice anymore
Ok
Yeah
So that’s, uh, the travesty, but, uh, uh, I believe that this is coming to the end
Ultimately, su, more and more doctors will learn what we do
Yeah
and more and more patients will benefit, and the breakthrough will come, but before the breakthrough will come, you have the toughest time
Mmm
because, the opposition is mounting the attacks
Whenever we came up with an announcement that was in the 20th century, we have such and such success, you are furiously attacked by the other guys, who are on payroll, uh, of cartels
Ok (laughs), for no apparent reason
You should be congratulated but we are attacked, because they see we are going to win, and they hate to see this because this means they won’t see money anymore for them, ok, or at least they think they won’t, they won’t have their payroll anymore
—————————————————————
Dr. Burzynski on publishing (6:18)
—————————————————————
So why does, why does, ev, everyone hide behind this thing of saying about publishing, because that’s the thing you hear all the time
Well, we cannot publish until the time is right (laughs)
Yeah
If you would like to publish the results of, of a
10 year survival, for instance
Mmm
Which we have
Nobody has over 10 year survival in
malignant brain tumor, but we do, and if you like to do it right, it takes time to prepare it, and that’s what we do now
What we publish so far
We publish numerous, uh, publications which were, interim reports when we are still continuing clinical trials
Now we are preparing, a number of publications for final reports
Eh, many of my publications were rejected by known publi, by known journals like
Why ?
like Lancet, like JAMA,
like New England Journal of Medicine
Why ?
Because they say: “Sorry, but you didn’t receive enough priority to be published“, and if you look in these journals and 1/2 of the, these journals, they are advertising for pharmaceutical companies
Obviously if this would come from a pharmaceutical company, this would be published on the 1st page
Mhmm
Ok
Because this, you don’t have objectivity with these guys
They are on the payrolls of the big cartels, ok, and again and if you try again to send, oh, oh, my manuscript to good journals, if they reject it, we go on Internet and you describe what are these guys
So then everybody will know, because I have very good evidence
that we tried many times to publish in 1st class journals, and we are always rejected
It’s just, persistent
And not, and not because of lack of scientific knowledge
No, because of lack of priority
And who has priority ?
The guys who are paying money for advertising
Ok
So that’s, unfortunately what I think will end sometime
—————————————————————
And we are now preparing publication, on some of these results
We have already published the results on the technique of very difficult variety of breast cancer, which is triple-negative breast cancer
Now we are preparing another article on the technique of
gynecological cancer, which is best series of over 100 patients treated with incurable ovarian cancer, uterine cancer, (?)
So this, has now been prepared for press
Eh, of course, I would like to, give everybody intravenous antineoplastonssee, if they qualified, but, this is limited by the government, because the government limits us to only the patients who are
have
brain tumors, but the other patients, they can be treated through this combination of medication which work on the genes
Antineoplastonswork on over 100 different genes
That’s why they give us, very good advantage
There are medications that also work on a number of different genes, and we can combine them together, and use them in the right way
So
that’s what we’ll continue to perfect, and that’s, uh, most of our patients
been treated with just combination of targeted medications
—————————————————————
The Future (9:00)
—————————————————————
Why do you continue to do this ?
Because you know the truth, and you want to get the truth out there ?
Absolutely, because we understand we on the right track
Somebody has to do it
I was lucky enough to, find out about it
We have evidence that we are right, and, uh, I don’t think, why should I stop if, people that don’t have sufficient knowledge, who are working, on behalf of some big business, would like to stop us
We are right, and we would like to continue to help people, and, uh, that is what is going to happen
Of course, probably the best reason to make a discovery, and let it stay as it is and ask the other people to publish after I die
Yeah
That’s what happened with the discovery of Nicolaus Copernicus, who was my countryman
Eh, his book was published, sss, when he died, and, uh, for good reason, because of such fears for execution of the people who followed him
like
Hmmm
Galileo, Giordano Bruno, that it took the church, uh, only until recently to agree that, uh, they made the error, in the case
Ok
So if you come up with some breakthrough, you have a choice
Keep it quite until the other guys who understand what you do
or try to use it
In my case, I decided to use it, because I would like to, help people, and now that we can save people, so why should I keep quiet, ok, but certainly if, my work won’t get published because it keeps getting rejected by some of the journals, then we wait until I die, and then we let the other guys publish it
So, ok
======================================
======================================
Pete Cohen chats with Dr. Stanislaw Burzynski
======================================
Pete talks with Dr. Stanislaw Burzynski
——————————————————————
December 2011 (1:02:30)
======================================
How did you kind of get into this, into this field in the 1st place ?
Uh well, it was a coincidence, ’cause obviously I made discovery of new chemicals, peptides which is in blood, and I noticed that they were deficient in patients with cancer, and there was a curiosity, why there was such deficiency, and I was interested what these peptides that I discovered, are doing in the body
So the connection with cancer was quite obvious
He, healthy people have abundance of these chemicals in blood
Cancer patients have varied to none
So could be that cancer is another deficiency disease
So
So when you found this out
Yes. Mhmm ?
how did you feel ?
I mean, did you not just want to shout from the rooftops, and could you believe that you’d actually discovered something ?
Not yet
Of course I was skeptical, and I found something that was interesting, but obviously, it was just the very beginning and when I shared this news uh with some other guys, who are obviously much older than me, who, other guys who were professors, who ever, so (laugh) they began to laugh so much they almost died from laughing
Ok ?
That (laughing)
Wow, this guy would like to kill cancer
Forget it
Ok ?
That’s just not going to happen
What are you doing ?
Yes sir (laugh)
Well how did that affect you ?
Well it didn’t affect me too much because I knew that uh the science uh requires uh some successes and uh setbacks and I felt, well I still would like to know, what these peptides can do, and I would like to know what they can do, not only regarding cancer but in various aspects of body function
For instance, the activity of the heart, the activity of the uh uh G.I. tract
Whatever
Ok
I needed to expand this knowledge
Suddenly I found some like 119 new peptide fractions
Nobody ever heard of them
So I wanted to know
What do they do ?
And when I was in Poland I couldn’t have really do any further testing, because I didn’t have such possibility to require different group of people who would do the testing, and simply by working in the biochemistry laboratory I did not have such capacity, and obviously the budget for doing uh research was extremely small
Besides, I was continuously harassed by the communists and they were sending me to, eh, the military, so I couldn’t do much
I still did whatever I could
Then I came to U.S.
Oh so you came to U.S.
What, what year was that ?
It was 1970
I heard you came with not very much money in your pocket
Uh well it was better than where I came first to the U.K., because when I came first to U.K., I came practically with nothing, and uh, when I went to British uh Medical Student Association, they were going to give me 7 pounds for one month stay in U.K. (laughing)
You were supposed to get this money in Poland
Yeah
(laughing) Sorry about that
So ultimately they decided to give me 7 pounds, and obviously at that time it was a lot of money, so with 7 pounds I was able to survive a month
(laughing) Good luck (laughing)
But in U.S., I was allowed by the communist government to $15, which again, was equivalent probably to 7 pounds, whatever (laughing)
So you came here with $15
I smuggled another 10
Yeah
So the proper balance was like
So what
So what did you do when you got here ?
Well, ehhh, when I arrived I was uh, uh, uh, trying to get ahold of my relatives
My uncle that lived in Bronx
Yeah
And uh I officially came to visit him and uh I was expecting him to see me at the airport, and surely enough he came to the airport but uh at the time he was an elderly man
He was close to 80, and eh, he probably went to a different part of Kennedy airport, so he couldn’t find me
So I was stuck in the airport
This was Holiday
This was 4th of uh September, which was a Labor Day, and so I couldn’t get uh uh to his apartment
So finally I spent most of this money for the cab, the taxi rides to his apartment
Some, like $13 worth
You had $2 left
Ye, Yeah
Plus the $10
Sure
Well, so then I stay uh I, I was obviously in the family’s, I couldn’t
Yeah
I, I don’t need to worry about it
So obviously I had a food and lodging, and uh, still I was trying to get hold of some of the people whom I knew were doing the research in the area, whi, which I was interested
Mhmm
which was peptide research, and uh trying to see if I can advance my research
And then I thought, well, if I go back to Poland, I didn’t expect to stay
And in the meantime uh my job at the university in Poland was terminated, and I wondered they needed my position for the woman who was the wife of the 3rd Secretary of the communist party
Finally when I was terminated from my job, uh, there was no need for me to go back, because I would not be able to find job anywhere in Poland, because obviously everything was controlled by communist
So that I decided to stay and to look for the possible, possibility for me to find a job in the U.S.
And wha, what job did you find ?
Um
So you were in New York ?
Yes, I was very active, of course since I was involved in the research
I knew the key people who were involved in peptide research
There were not many of them, but at least there was one good team in New York and Columbia
Um, there was another one at, uh, Cleveland Clinic, and there was another one in Houston, and so, uh, I check with all of them and, uh, the place in New York was unavailable because they hired, um, somebody, um, about a week before I came
Uh but uh, uh, I was invited to the interview to Houston
I was surprised but uh, prepared for my trip and I arrived to Houston and had interview with a professor at Baylor College of Medicine and he gave me the employment, and so it was relatively simple
And then what were you doing on like a day-to-day basis ?
Uh, well, uh, when I arrived to Houston I uh, obviously received a job
I received the job as “Research Associate,” and um, obviously this was associated with a reasonable salary, but the salary was paid once a month, so I had to think, what do I do for the 1st half of the month, because I came in the middle of the month, and didn’t have any money (laughing: both), but some good people loaned me some money so I, I have enough money to rent the apartment, and finally after I got my pay, I was able to do quite well, and I was able to advance, uh, in peptide research
So were you able to do your own research or
Absolutely. Absolutely
that they wanted you to do ?
Absolutely, and uh, I was quite lucky to join the team of the famous professor
Professor George H
er, uh, who was initially professor of Sorbonne in Paris
Then in World War II he emigrated to U.K. and he was professor at Oxford, and so finally he came to U.S., and, uh, he put together the peptide research team
He needed people who know how to do analysis of peptides, so that’s why he hired me
And uh I uh told him that I have my own project, which is peptides, and if you wouldn’t mind that I do some research of mind, and he agreed
So basically this was gentleman agreement that I will spend 50% of my time working for him, and spend 50% time, working in my area
Uh, the equipment and the instruments were the same, so it wasn’t too difficult
And then you, and then when you had something to show then, when. when you had even more of something to show them, how was that received, because you see, I’ve really got something here ?
Ah
I think I’ve got something here
Absolutely, it was received with great curiosity, and, um, and obviously he needed people who could use, the cutting edge, uh, methods for peptide analysis, and that’s what I knew about, but I couldn’t use this for him because I didn’t have funds to do it, but I knew exactly what needs to be done, and on the other hand, uh, this was great surrounding because just across the corridor, another team receive a Nobel Prize for working on peptides
The only problem is, uh, one of these researchers uh was of Polish origin who received Nobel Prize for peptides (laughing)
Yeah
began, uh, fighting with the other one and finally his job was terminated because he punched (laughing)
Punched him ?
the other guy in the nose (laughing)
Yeah
Huh
So, but the good thing about it is that ultimately I inherited uh, their equipment
Yeah
for peptide research, so
Wow. So that must have been like a, like, a, a child in a sweet shop
Absolutely, so was a great coincidence so
So then you were really able to, to, to, to look at it in more detail, and ?
Absolutely, so then of course I was really out of work uh, and the team of Dr. Unger, and also, uh, I was spending a lot of time, uh, progressing in my research, which was very important uh, of course it means long hours uh, ’cause of, uh, 8 hours I would spending working for Dr. Unger and probably not 8 hours until midnight working on my uh, project, but uh, I enjoy it
In the meantime I need to prepare for exams because I wanted to have a license
So I was lucky because uh, within 3 months I was able to pass exams to uh, to naturalize my diploma, and then uh, just, uh, the day, on the eve of my birthday, on January 22nd, President Nixon had a speech in which he promised American people that by 200th anniversary of America, they would have a cancer cure, and no limits would be set on the funding
So then I thought, well, if that’s the case, perhaps I should apply for the grant also, and I did
It was crazy idea because I could barely understand when the people were talking to me (laughing: both)
Well I decided to put together grant application, in to the National Cancer Institute, and include the project on the peptides which I discovered, and I was surprised when this was approved
So then in uh 1971 I get approved as Principle Investigator, to do the project, which included eh, the top people from M.D. Anderson Cancer Center, and from Baylor College of Medicine, um, and I was supervising this
I was at that time 28 years old, but I was supervising the guys who were famous, and who were some like 60 years old (laughing)
Wow
and so the money was coming to me from the National Cancer Institute, and I was uh daily uh, running the project, sharing, obviously with the guys from M.D. Anderson, so, and going ahead with the research, so
and of course at that time I was disappointed to have to (work ?) with M.D. Anderson and Baylor, and then I could move independently what I was doing
So at what point were you actually, able to start testing on people
Mmm
It took a long time because
I mean you couldn’t wait, right ?
Yeah it took a long time because obviously um, initially you have to go through a lot of pre-clinical testing
The 1st time it was uh, around the beginning of ’77, yeah
So then we began phase I clinical trials, and this phase I clinical trials were approved by one of the very good hospitals in Houston, which is part of the hospital chain American Medical International, and they interviewed my project and their Institutional Review Board approved it for clinical trials
Well then I did my 1st clinical trials, phase I clinical trial, with a medication that I am not using at this moment because we made further progress of course, at a hospital, and this hospital at that time was called Twelve Oaks Hospital
At this time it’s called River Oak Hospital
Yep
Yes
And then, at what, at what, was there a time where you realized: This is actually working ?
Well, now this was in 1977, and (laughing) surprisingly, uh, uh, perhaps one of the 1st successful case where you can really, document a clear-cut improvement by doing the scan before and after
It shows tremendous decrease of uh, uh, tumors which corresponded to colon cancer which spread to the liver
(This guy was ?)
(laughing)
(?)
(laughing)
And uh, his case was so interesting, that when I sent it for press, the editors decided to put us on the cover, of the journal, the scan
Yeah
They decided to put on the cover of Science, showing the tumor before, and, after the treatment
Eh, so this was uh , obviously
And then what happened ?
Didn’t that m kinda, didn’t word spread like wildfire and people, more and more people want to come and see you ?
Ah, Absolutely, well the 1st excitement occurred, basically what the President Nixon promised ok
That he would deliver
Yeah
cancer cure uh, by ’70, uh 6, 1976, and we did, ok, and we did deliver cancer cure
Yeah
by 1976, 1977 ok, and um, the um, main uh event was the presentation of uh our theory on our research, on perhaps one of the largest uh scientific (congress ? conference ?) in America, involved 19,000 uh, researchers attended
Eh this was annual meeting of the Federation of the Societies of Experimental Medicine and Biology
It happened that at that time it was in Anaheim, California
Uh, I sent uh, uh, the abstract of my presentation, and I was simply, patiently waiting until this would be shown, which was in ’76
In June ’76 right before 4th of July, and uh, I was surprised when they notified me that um, my abstract was selected out of one of few, which was in great interest of the news media, like Associated Press, for instance, and then when I did my presentation, then Associated Press decided to make a release of this, and then you can read about it in newspapers all over the world
In uh, (laughing) distant places like Buenos Aries, receiving CBS newspaper clips from all corners of the world
And what was that like for you ?
I mean, how did that feel, just to see that your name was, all over the world ?
This was the 2nd time, what (?) this happened to me, because 1st time it made such news, by working on brain peptides with Professor Unger; this was around ’72, and suddenly, this wasn’t so much of my
Yeah, but still it was your (interest ?)
involvement, but I was working together with Professor Unger, and we made a great news, by discovery of, certain peptide in the brain, and then it spread all over the world, and then again, uh, uh, CBS
What was that like ?
I mean, how did you feel when you saw ?
Well, uh, it was surprising because uh suddenly we got uh news people coming, and the TVs from various countries, especially from Europe, for instance, from variety of corners, like from Europe, from New Zealand, from Brazil
You name it ok ?
Eh, so there was a great excitement about it, but 1st time that this excitement happened was, is around ’72, uh, really, eh, is typically what happened after such excitement, is the ? iation ?)
ok
Yeah (laugh)
Well, uh, (laughing) the uh, establishment is and this um will attack you and will try to destroy you
Did you know that was going to happen before ?
I knew it would because in Poland, uh, my father’s, uh, gave me the book of um MIT Professor, uh, Thomas Kuhn
(here’s a guy ? try to translate to (?)
(laughing)
(?) yeah
Yeah, probably
(laughing) sure
and then uh, this was uh, the book which was titled eh, Structures of Scientific Revolutions
It happens that this book was translated to Polish language as couple of years after it was printed, in U.S.; which was around uh, I think 19 uh, 64 probably, ok
So then I read the book, and the book shows uh, how, eh, the paradigm shift occurs, ok, and the, it never fails
It always goes through the same stages
1st it’s short period of excitement, and the a long time of harassment and persecution, and then finally the brief period when uh, uh, if you survive, then uh, the other people say
well it’s obvious
We always knew (laughing) that this
Yeah
was going to happen, ok ?
So I knew what was going to happen, uh, but uh, it was hard for me to believe it uh that, uh, in the 20th century, 21st century it could happen, ok, but then uh, when uh, I began going through this, it was like going to some uh, unpleasant disease
You read about it in the books and
Yeah (?)
then uh, you finding one symptom after another, and it affects you
Yeah
and you know that it could be deadly,
(?) survive
Well you could have ended up in prison, right ?
Yeah
(?)
You may die before uh, you be able to do anything
Mhmm
So the advice of the author of the book, was that you have to start early to make some medical discovery, because you probably have years of harassment in front of you, and probably the best chance that uh, you get accepted if you live longer than your opponent, because some guys will never accept you (laughing)
Yeah
until they die
So that’s what happened
Well then, of course, I witnessed what happened with Professor Unger
Yeah, he made the great news, and obviously I contributed to what he had, but he was uh, my boss, and then obviously I did not much, suffer much from retaliation, but he did, ok
So there was retaliation, and uh, they accused him of everything possible, uh, finally causing for him to move from Houston to Memphis, Tennessee, eh, zzz, about year later he died
So unfortunately his research was never brought to the time when it was accepted, ok
It was great research, ok, and if had really to more resource and time I can bring this to be accepted, because this isn’t a completely different field
This is brain function, memory, and peptides working in the brain
But at that time unfortunately the project was killed, which is great loss for humanity, eh, ’cause the discoverer passed away, and the product was gone together with him
It can be still resurrected, and I think it will be
Eh, so then, for me, eh, it meant only advancement, unfortunately, because, uh, when uh, uh, he was stripped from the funds, I received funding from the National Cancer agency funding from the university, and I was able to support him, because he was stripped of his grants and funds
So he was able to move forward with his research, but finally when he moved, I inherited very large laboratories
My laboratory was located in 3 buildings
So the lab space and uh, uh, some prime location, in the medical school
So then I did very well, then, of course, the publicity occurred, and this publicity was centered around me, not around both of us
Yeah
at that time, in ’76, and then again there was about 1/2 a year when there was a great enthusiasm, uh, good wishes, whatever, and after that, a retaliation occurred, ok
So then obviously
Mhmm
And what was, what, what was at the heart of the retaliation ?
Uh, well,
The fact that their people didn’t want this to come to the fore ?
Initially there was some overtures to take away the discovery from me, and uh, for instance, uh, uh, uh, Baylor College congratulated me
I received diploma, so suddenly became superstar, ok (laughing)
Yeah
and then, of course, uh, the wise people, the business people from the university said: “Look, probably we should talk now about patents, we should talk about pharmaceutical companies, we should try to, somehow, put this to motion,” ok, and that’s what we did
So then uh, we talked to some of the best lawyers in the country
Of course, uh, the university uh, are in control of this
There were visits of uh, pharmaceutical companies
I remember one of them came from the research center in U.K., from High uh, Wycombe , and this was so (encouraging that ?) was very interested, what we do
But then uh, the intention was just to take uh, my, uh, in, invention away from me, and obviously
Mhmm
I would have very little to, to, do to promote this, to develop this any further
So I thought about it and I felt that I’m not going to do it
There then uh, I was offered to join the mainstream cancer research at Baylor cancer medicine, and obviously uh, I would receive much better title, of professor
Yeah
and obviously there would be much better equipped laboratory, but again eh, they wanted me to, completely quit private practice of medicine, ’cause at the same time I was practicing medicine, which many researchers were doing
I was working at Baylor College and then I was practicing medicine uh, outside Baylor College, in the group of the other doctors
So in this way I had some independence, because obviously, I could always practice medicine (laughing)
And did you always want to keep your independence,
Yes
and did you know that was always a good thing ?
That’s right, that’s right
Because I, I did not want to be uh, at the mercy of the university or the government
Uh, but I still wanted to stay in academic surrounding, because obviously I came from a family which has great tradition of academic careers
So that’s something which obviously my father was always telling me that I should be really staying in the university, ok
Eh, uh, uh, but finally I decided that I was not going to accept this offer because uh, why should I resign from my private practice
Mmm
It didn’t hurt my research in any way
So I decided to continue, and uh, then that’s when the retaliation occurred, and uh, I was (crazy ?), harassed, and attacked, and finally
And how were you harassed ?
I mean, letters or (peop ?)
Mmm, well, as I could do the research for such a long time, because really, this was some like 7 years at the university, because uh, very few people in the university knew what I was doing, because I was only responding to the National Cancer Institute, and uh, I was not part of the mainstream cancer research center
What happened is that uh, (laugh) I was employed by the Department of Anesthesiology, which obviously, on the surface has nothing to do with cancer, but, who cares ?
I was receiving grants from the National Cancer Institute, and so Anethesiology was a very wealthy department, and they had a lot of space, but they were doing very little research
So they wanted to do some type of research, and uh, the chairman of the department was supportive of my doing cancer research
So basically I conducted uh, Anethesiology
laboratory into cancer, into cancer research laboratory, and very few people knew about it
They learn about it
when uh, the Associated Press (laughing) broke the news
So then uh, the retaliation happened
Mhmm
and then they wanted me to join the mainstream, but obviously I was enjoying very much (laughing) working, in peace and tranquility, and responding only to the National Cancer Institute
So then uh, what happened at that time was that uh, obviously Dr. Unger, moved to another university, and um, uh, the chairman of the department uh, his uh, uh, employment was terminated, because it uh, he was involved in uh, the war between 2 superstars of (the ?)
One of Dr. DeBakey
and the other one was Dr. Cooley
They were 2 famous, eh, eh, cardiovascular surgeons, who were competing with each other
Ehhh, Dr., eh, the chairman of the department, was on the side of Dr. Cooley, but the boss of, uh, Baylor College was Dr. DeBakey
So after Dr., Dr. DeBakey
learned that, uh, the sympathy of Chairman of the Department; which was Dr. Cooley, his job was terminated
So then they, took another man; very old, professor, who was already retired, to be the chairman of the department
They, he knew nothing about, any type of research (laugh), especially cancer research, and, uh, once I decided to not join the mainstream, Baylor Research Center, eh, the people who are in charge of Baylor Research Center, they put a pressure, on the new chairman of the department, and they frightened him, saying look, you are, uh, in a charge of anesthesiology, but here’s a guy doing cancer research, eh, and see this was a great, uh, like liability to you, and pretty soon he may be sued, uh, without knowing what he’s doing
Ok
So then, uh, they, they, um, brainwashed the old man, and he decided to strip me, slowly from my laboratories, eh, and, and, harass me
Ok, uh, ultimately, he sent me the letter that, uh, in which he informed me that he does not see any connection between, uh, my research and anesthesiology; which was obvious, eh, but obviously I was doing the research which made the university famous, more or less
Yeah
So then one thing to another, and I decided, no, I am not going to work with, in this environment anymore, and I decided to do, try to do on my own, to start my own laboratory
So that’s what happened
Ok
And then you did that ?
You had your own, laboratory ?
Yes, and then I decided, this was just the beginning of 1977, and, uh, e, we put together a laboratory; of course I already had private practice, and, uh, I was still working
In your private practice
Yes
you were still seeing patients ?
Absolutely, absolutely
Seeing any results ?
Yeah, seeing patients, getting results
I began phase I clinical trials
Mhmm
in the hospital where I was seeing patients
I had patients at that time, in about 2 or 3 different hospitals, uh, but the hospital, where I get permission to do clinical trials, was a most supportive, and that’s why I did it this way, and, uh, obviously it was necessary for me to build from scratch, the laboratory, the research laboratory
I decided that I just, uh, I just, uh, make some funds in, our private practice, and at that time, of course, this was just, um, general (?) private practice, internal medicine private practice, em, and, uh, the funds which I produced in private practice I can use to, put together the laboratory, and that’s what we did
Ok
Step by step we build the laboratory, and we expanded our private practice
So basically, I switch from the government and then I found it best to fund the research, just privately funded research, which nothing unusual, thhh, some like 50 years before everyone was doing it
Everyone is doing this
Yes, and there’s still some people, especially in the U.K., who are doing this
Ok
Yeah
Um, the most of the discoveries were made through the, sss, through the research that was funded, by the researchers
Mhmm
There are also some, wealthy people who donated the money to do it
So only after World War II, this was, um, the system was created where, the researchers became, um, really became the slaves so, the government
Mhmm
and pharmaceutical companies, and new companies, and if they do not receive the money, they couldn’t do anything
This way I could have independence, and, uh, do whatever I want
Yes
So at what point did it get to where, action was taken against you, and you knew that you were going to have to go to court ?
The action, um, um, started very soon, and the, and began at the lowest level, which is like, county level, and then you go obviously
Mhmm
higher as you move along, and when, uh, I was leaving, uh, the university, the chairman promised me that (laugh) when I leave, uh, the obviously, quote, unquote, “They will bust my ass”
Ok ?
Yeah
(laughing)
When leaving the university
When I was leaving the university ?
Yeah
Yes
And, uh, he promised me that, uh, they will trigger the action from Harris County’s Medical Society; which is probably the lowest level of harassment and just, the somewhat prestigious society if you are are a good doctor practicing medicine, in Harris County, where Houston is, then you should be a member of the Harris County Medical Society
Uh, if you are not a member of Harris County Medical Socity they won’t grant you privileges to see patients in hospital
So this was important to be a member of the Harris County Medical Society because I was practicing medicine
Why do you think
Why do you think they wanted to stop you ?
Why did’d they wanted me to stop ?
Yeah
Well, probably just for the heck of it
I don’t know
(Laughing: both)
Ok
Well do you think they were threatened by you ?
Well, I doubt it
Their probably some type of revenge
Ehhh, since I didn’t yield to their harassment, and I decided to do whatever I was doing, and decide to do it on my own
Mhmm
and they felt, well, let’s try to kick his behind if we can
Ok
Yeah
Well I don’t think I was, uh, causing any threat to them at all, because this was really, large institution
So it escalated ?
Yes
Just starting at the lowest level
It was, eh, unpleasant because they were dragging me to like, holy inquisition proceeding, explain what I was doing, and basically they’re trying to force me to stop what I was doing by using various ways
Obviously they didn’t have any, uh, reason to do it because, uh, my clinical research; which I was doing in the most, done under the supervision of, Institutional Review Board, and before I started anything I asked, uh, I retained medical lawyers, and I asked them to check, if I can, uh, for instance, do the research to use medicine, and use it, in a patient, and they
checked with this, State authorities, Federal authorities, and at that time it was perfectly alright
So I was doing, everything, legally
So, they really couldn’t do much, but, they were harassing me, asking for me to give them a lot of documents, whatever, and suddenly, all of it stopped
It stopped because they were exposed by news media
Yeah
So, when the article was written about it, they disappeared from, the horizon, and then they never, harass me since then (laugh)
Yeah
I think it’s, lasted probably for, 2 or 3 years, and then it was gone, so
And then, and then how did that end up ?
How did you end up going to court for the 1st time then ?
Oh well, so obviously there was no, uh, issue of going to court at that time, it was only the issue that, I might not be a member of, uh
But you might not have been able to practice medicine
the medical society, and then I would not be able to see patients in the hospital
Ok
So this was deliberate, ok, and at that time, m, most of my patients were treated in the hospital, because I didn’t have yet the system to use treatment outside the hospital, like for instance the pumps that we are using now
They did not exist at that time
So it was necessary to use I.V. posts
Mhmm
and, uh, and heavy pump, heavy treatment
So then, uh, so this was, uh, it started around ’78, it continued for a couple of years, and then nothing happened after that
I was visited by, um, FDA people, but we have pretty constructive meeting
They didn’t bother me, and, uh, the next attack occurred in a 1983, and this was by, uh, Food and Drug Administration
So, suddenly I was sued, and, um, they really wanted to put me out of business
Ok
They didn’t just want to put you out of business
I mean, they wanted you, they wanted you to go to prison
No, in ni, 1983, they wanted me out of business
Right, just out of business
Yeah
Don’t want you practicing
Shut down, what I am doing, and they did it, secretly (laugh)
Most of this actions occurred around, uh, just before say Passover, and Easter
Ok
Yeah
Every year
It never failed
Ok (laughing), a, and a usually they were attacking, uh, uh
Someone
No, no
For instance it happened for instance I was away, and, uh, they were filing papers in court, like, um, around 5 p.m. on Thursday, ok, and Friday was day off, because was big Friday, Good Friday
Ok
So then, obviously, um, they then
realized I’d be away because I participated in some T.V. program, and they want to do it while I was away, but, uh, it so happens that
a one of the friendly lawyers was in court at the time, and he overheard whatever they were doing, ok (laughing),they were going for injunction, ok, and so then, uh, I would be stopped immediately
I wouldn’t be able to do much, ok, until the judge would reverse it, but, uh, he read about it and he prepared immediately temporary restraining order, and filed at the same time (laughs)
Yeah
So then, uh, I could practice without any interruptions, but, uh, then, of course,
So do you think of all the people that were trying to stop you
Yeah
Do you think any of those people actually, really, genuinely believed that you were causing harm to people
Hmmm
or do you think that they were just stopping you because ?
I think some stupid people,was at the lower level, like, uh, uh, some lower level FDA agents, they didn’t know what they were doing
They were manipulated, ok, but the guys who above, they knew very well (laughs) that, I was right
They knew what they were doing
Absolutely
They knew you were doing something
Absolutely, yes
groundbreaking
They knew very well, and that’s the reason why they attack me
Ok
Yeah
It’s obvious
So this 1st encounter, was relatively brief
Uh, we went to court, which was Federal court, and the judge, uh, would rule in our favor, and the judge, uh, uh, in the verdict, uh, cleared me from any, of the charges, and, uh, I found that I could, uh, I could treat anybody, by using my methods, but I cannot really, uh, sell medications outside the State of Texas, and that’s what I was not doing anyway
So really,
the judge
affirmed what I was doing
Right
That I’m free to use my invention, and treat people in the State of Texas, which made, of course, the government, uh, people furious, and they threatened the judge
They send the judge a letter saying that, if the judge will not rule their way, then they will go after me with criminal investigation, uh, with seizures, uh, eh, grand jury investigation
That’s what they did as the next step
When was the next step ?
How many years later was that ?
Well again, there was some like couple of years when it was relative quiet
Of course, in order to be, eh, in, eh, in order to do what I was doing, it was necessary for me to have inspection, by the inspectors, approved by the FDA, who
check our manufacturing facility, and, ah, certify that what ever we do, we do right, and there are no discrepancies
So this was obviously something, very difficult, because obviously we knew that the FDA inspectors
will always find something wrong, you know
Yeah
So these agents are trained to always find something wrong, but anyway, at inspection, uh, found we are doing everything perfect
Ok (laughs)
So we were able to pass the inspection
Uh, we are in full compliance with what is called good manufacturing practices, and then everything was quite until about 3 years later when, uh, there was a raid on our clinic by the FDA, and seizure of, ah, medical records, and then there was another, uh, obviously, ah, another, uh, part of the war began, and then, uh, we file a lawsuit against FDA, and, uh, as a result the judge forced the FDA to give back some, of the documents, and permit us to, uh, be able to copy the rest of the documents, and so then, uh, FDA began a grand jury process, and, uh, there was some, like 4 different grand juries, uh, ah, which did not find me, guilty of anything, and then finally 5th grand jury was able to indict me, which was in ’95
Ok
So when you were, when you were going to court; because I remember seeing in the
Yeah
Burzynski, the movie
Yes
I remember seeing in the photographs
Yeah
around here
Sure
there were lots and lots of people outside there (?)
Yeah
What was that like to see that ?
Oh well, ah, this was, uh, going for ever, going to court, and obviously I was going before this grand jury investigation, whatever, but ultimately, their lawsuit, uh, the trial began, in, ah, January of ’96, and, uh, it took a number of months
Ok
So I was going to court almost every day, and the people realized what was going on, and they were giving us a lot of support
So then you can see people outside the court
What was that like to see your patients ?
Well it was, ah, it was, ah, very good, uh, uh, show of (laughs)
Yeah
patient solidarity
They wanted obviously, to help us, and they knew that, uh, they have the power, and, uh, they knew that they were fighting for their lives
Ok ?
So they, uh, were dedicated people
It wasn’t easy because this was winter, and it was raining, and so it was cold weather, but obviously
Were you prepared to, to face what you could have faced, you know, that you actually could have gone to prison ?
Sure, yes
I, I knew, but I was, convinced that I am going to win
So, should I, obviously, statistically it was, uh, highly unlikely, but, uh (laugh)
Do you think that this will stop one day ?
That people will just get off your back, and (laugh)
(laughs)
you know
(?)
and can see what you’ve done
(?)
and, and see that there’s really something there
Absolutely
This is just the (?)
Absolutely, absolutely
I
That’s what I was convinced was going, to happen, and, uh, I was convinced that we are going to win, with FDA
Good, ’cause I mean, anyone does any research
Yeah
you know
I had this on here
Yeah, sure
which I’m sure you’ve seen, like on Wikipedia
Yeah
and what it says
That there’s no convincing evidence
Yeah, sure
that a randomized controlled trial has, you know
That your work, that, that there’s nothing there
Yeah
What’s that like when you come across that stuff
Do you just not read it, and just
So (laughs)
Simply don’t pay attention to it, because it, it’s not true
Ok
Yeah
You won’t be able to, do any, clinical research which we do, without convincing evidence, especially when you have the most powerful agency in the government which is against you
They’re against you, but you’ve been working with them for, for
Yes, so since 1997
Yes, but you see
Yeah
Obviously they didn’t have any sympathy to us because they lost
So they would love to find something which is wrong with what we are doing
They would love to prove that the treatment doesn’t
Yeah
So this is, very difficult
Ah, so the fact that they’ve, um, agreed that what we have has value, and they allow us to do phase 3 clinical trials, it means that we are right
Ok ?
Yeah
Because, uh, uh, nobody who didn’t have any, concrete evidence that it works, would be able to go as far
Ok
Yeah
So whatever Wikipedia says, well, I don’t care for them (laughing)
Ok, so, we, we talked a little bit about, what you, where you’ve come from, and what you’ve been through
As far as your treatment, um, to cancer, and this I’m very interested in, and why you don’t think high doses of chemotherapy is, is particularly helpful for the body, and what
Well it is generally wrong approach
It can help, some patients, wi, with a rare form of cancer, but only, eh, in limited capacity
Those who, are quote, unquote “cured”, usually die later on from adverse reactions, of chronic adverse reactions from chemotherapy or radiation, or they develop secondary cancer
So certainly, there is, this is not such a cure which you have in mind, that, use the treatment, patient recovers and lives normal life
Such cure does not exist for patients who are taking chemotherapy or radiation
They will always suffer, some problems
Either from cancer, or radiation, chemotherapy, and there is only small minority of patients who have advanced cancer who can, have long term responses
So obviously, this is unacceptable treatment
Of course, it was important at certain stage of development, but now, of course, uh, when we know more about cancer, it’s becoming, uh, unacceptable, and I think it will disappear, from the surface of the earth, in another 10 years, or 15 years, and, uh, in the medical textbook, this will be described as strange period of time, when people were using some barbaric treatment
Ok
Mmm
You have a number of different ways of treating cancer
So, one of them is the antineoplastons
Yes
This, this, this is the peptides
Mhmm
The, the this is the thing that my partner is on at the moment
Sure
in the clinical trial, and, uh, you’ve had some real great success
Mhmm
using that
Right ?
Yes
But you also have
Mhmm
another way, of, of, of treating, which is, using, it’s using some sort of chemotherapy, but in low doses
Well, um, um, whatever we are using we are using treatment which works on the genes
Antineoplastonswork on the genes, and they work on about 100 different genes
So what are they doing to the genes ?
Well, they work as molecular switches
They turn off the genes which are causing cancer, and turn on the genes which are fighting cancer
So, that’s what they do, and they produce this in about 100 different genes
It’s not enough, to control all cancer
Actually you can control some cancers, but not all of them, because you may have, numerous genes involved, in cancer
Well, for instance, in average case of breast cancer may have 50 abnormal genes involved
Uh, in, uh, like grade 3 brain tumors, for instance, anaplastic astrocytoma you might 80, or might be 100, but if, uh, you go to highly malignant tumors like, glioblastoma, you have, probably about 550
Eh, if you don’t cover such a spectrum of genes, you won’t, you’re not going to have good results
So that’s why, we know from the very beginning that we have some limitations
We can help some patients but not all of them, because, they have involvement of different genes which are causing, their cancer
So then you can still have these patients who are combining the treatmentof antineoplastons,with different medications which are in existence, which work on different genes, and this includes also some chemotherapy drugs, which are available
Eh, so this means that, um, for the patients for whom we, cannot use antineoplastons, because they are not in clinical trials, then we are using combination treatment, which consists of medication which already, approved as prescription medications, and, uh, by using the right combination by knowing which genes we need to attack, we get much better results
Now this also includes chemotherapy, but we never use, high-dose chemotherapy
If necessary, we use low-dose chemotherapy, and when you use low-dose chemotherapy you don’t have, uh, toxicity, which is, bad
We use this for
patients continuously, without much problem
So, so one of the main reasons of using low-dose chemotherapy is to try and keep your immune system strong, as well ?
No, to try to quickly decrease the size of the tumor, in combination with the other medications
We can use, for instance, low-dose chemotherapy and another medication which will increase activity,of chemotherapy, and as a result, you can have, as good, uh, uh, decrease of the tumor, with the low-doses
when you use heavy-dose
Well, there’s nothing unusual about it
For instance, uh, many doctors are using medications which are quite toxic
Mmm
And they, if they use the dosages, it’s helpful to the patient
The question is, what dosage will you use ?
If you use the dosages which are not toxic, it may still help the results, for instance, eh, the medication which was introduced, in mid, uh, 18th century for a particle for heart failure, in U.K. by
Dr. Withering, which was digitalis extract
Obviously it was highly toxic medication
It can kill people, in dosages much smaller than chemotherapy, but if you use the right dosage, it can help people
It was helping people for over 200 years
So those are the question
What kind of dosage do you use, and what combination do you use, and then, it can be useful
How did work that out then ?
I mean, how did you work out
Mhmm
that using small dosages of chemotherapy, could be effective ?
Uh, well, uh, it’s not only based on, uh, our research, it’s based on the research of the other, doctors
There are numerous publications on the subject, and in many cases the low-dosages can be used more effective than high-dosages, and, uh, on the other hand, by doing genetic testing, we can identify, which, uh, medications are the best for the patient
‘Cause you use
(?)
’cause you use a lab, in Phoenix
Right ?
Correct, yes
And, and how did you find out about them ?
Um, how did you ?
Yeah
Well, uh, uh, frankly speaking (laughs), 1st time I find about it by, treating patients who’s referred to us by one of the best oncologists in the country
He was usually treating some movie stars (laughs)
Yeah
and I found that this patient had, uh, genetic testing done, and I got interested in this, and I found about this laboratory
It was some time ago, but anyway, while we were doing genetic testing before, but, uh, we didn’t use this laboratory yet, we did it, through some other laboratories, and such testing was much, much simpler
So, we are using such testing, for a number of years, but in the capacity we are using now, this is really the last 2 to 3 years
So what happens is someone’s, bit of their tissue gets sent off to this lab ?
Yeah, the tissue is sent to the laboratory, and, uh, they do, testing on the entire genome of 24,000 genes
They identify the abnormal genes, and they go in-depth, by studying what happened to these genes?
Are they mutated ?
Are they amplified ?
And then from this, we have, a lot of information, and ultimately we like to know, which medications we can use to treat genes
What we are doing, we are treating genes, rather than, the tumor, as such
Mhmm
And, uh, if you identify all the genes that are involved, and find out which medications we can use, we can have very good results
And that’s what you found ?
That’s right
So in some case you’re treating people that might have a certain type of cancer
Yes, mhmm
with a drug that was designed for a different type of cancer
Uh, that’s right, because we are treating the genes, and, uh, if you find out that, this particular patient has, uh, an abnormal gene, which is not typical for this cancer but we have medication
Hmmm
that works on this gene, that’s what we use
So I would imagine that to treat, uh, that to treat people, this way, is obviously the future
Everyone’s different
Everyone’s genetics are d, d, different
That’s right
genetic markers, but to treat them that way, would require a bit more work
That’s, uh, obviously (laughs) (a life’s ?) work
Uh, uh, we’ll, like, uh, not just simply for, eh, uh, 4 different types of lung cancer
Yeah
Maybe 100,000 different types of lung cancer, each with, different, uh, genetic signature, ok, and once you identify this, then you can treat, such patients logically, and have good results, and if you do it on the scale of, uh, the entire country, this would, uh, give you much better results, and, uh, great savings, because
Mmm
you won’t use expensive medications for everybody, but perhaps for 10% of the population, and then for this 10% of population is going to work
Yeah
Which means that these people will avoid disability
They won’t spend time in the hospital
Uh, they will have short course of treatment, and then they go back to work
So the government would understand, uh, that’s something that can give them a lot of savings
I think they will go for it
Eh, gene testing, eh, at this time is still, uh, relatively expensive
It’s covered by, uh, the insurance of the United States, but for people outside, may cost 5500 euros, for instance, but I think it will be substantially less expensive in the near future
I think it will be below $1,000 for complete testing
So for running the test, uh, uh, eh, and, uh, finding out which treatment, has the best chance, you can save, 100’s of 1,000’s of dollars for individual patients
Yeah, but obviously pharmaceutical companies probably wouldn’t be too happy about that
No, no
People aren’t going to be taking their medications anymore
Well obviously be mostly happy that they can sell a lot of medications, but some of them are beginning to pay the attention, because they have to, because if they don’t, their competitors, will pay the attention
Mmm
Obviously, they would like to have, possibly, the best possible results, in clinical trials, so now they begin to screen population of patients for clinical trials, and do some limited, genetic testing, but, so, of course, they do it, uh, for the better of clinical trials so have best results
Yeah
Doesn’t mean that they’ll do, do it when they sell medicine, to millions of people commercially
They may forget about mentioning this medicine works the best for
Yes
this population of patient (laughs)
So what’s your, your vision ?
Wha, wha, what do you, striving to achieve ?
Well what I am trying to achieve is to introduce the way we treat patients, in, in various countries in the world, and, uh, what this would accomplish is, 1st of all, much better results of the treatment, much simpler treatment where perhaps only 1% of patient would need hospitalization, which would, uh, result in great savings
Uh, the treatment, uh, will be done for shorter period of time
For instance, few months to get rid of the tumors, then, uh, perhaps a year, to stabilize the results, and then go back, working and living, ok, without cancer
This, uh, genetic, genomic testing would be absolutely done for every patient who will come for treatment, to identify, what is the best treatment combination indication
So that’s what I would like to foresee, and then, of course, um, immediately, you substantially reduce, the expenditures for medical
For instance, if, you assume that in the mid, medium-sized country, will spend, for instance, a billion dollar, for, socialized medical treatment which will coincide with hospitalization
Ok
Uh, then, uh, most of the cost is for hospitalization, and services necessary for keeping the patient in hospital, then treating adverse reactions, which are, occurring because of the poor selection of medications
Eh, then if you switch to the outpatient treatment because you use medications which are not going to give such bad, side-effects, because you select this medication based on genomic testing, ok, and then immediately instead of a billion dollars a year, you cut down your expenditures to about $100,000
Yeah
100 million dollars
Ok ?
Probably slash it 10 times
Ok ?
And then people will be happy because, ah, the don’t need to stay in the hospital for a long time
They have less adverse reactions
They can go to back to work, much sooner
Ok
So that’s what I, can foresee as, the treatmentin the future
Not really hospital-based treatment
Mhmm
for patients, and most hospitalization is required because of adverse reactions from chemotherapy, radiation, but outpatient treatment, much easier treatment, also
medication given in tablet forms, for instince
And that’s what you’re doing here, right ?
I mean
Correct, yes correct
Usually in hospital, only, perhaps, for, one or two percent of patients, and, we would like to avoid it because when the patient goes to the hospital, he can pick up, some in-opportunistic infection, and then we are talking about more problem
Of course, I believe detection of cancer will be very important, because you don’t want to, uh, have a patient who is so advanced that he is fighting for, life, and he needs to be in the hospital
Ok
Yeah
If you had diagnosis in the early stages, then the patient does not need hospitalization
He can be treated very easily, then go back to work
So that’s the issue
And of course prevention is another important issue to us
To identify, changes in the body, which may indicate that the patient has already, early stages of cancer, also based on genetic tests, and get rid of this by using, behavior modification, by using proper diet, by using supplements, whatever, even without any medications
So, you’re obviously very passionate about what you do
Right ?
That, that’s my question about that
Well, I think it can help s, people in a great way, and, uh,
Well it can, I mean
Yeah
You have had so many su
Yes
I mean, I was talking to my girlfriend
Yeah
the other day,
Yeah
I mean, people, you know, you hear people say, this is a scam, and I was thinking, well the, if it is a scam
Yeah
it has to be one of the biggest scams ever
(laughing)
because all you’ve gotta do, is look on the walls
Yeah
and you look at those photographs
Yeah
Perhaps, this won’t surprise you
I’ve spoken to some oncologists just in the U.K., and they say, all of these people that you have helped, they either ever had cancer in the 1st place
Mhmm
or they were misdiagnosed
Yeah
or, uh, they went into spontaneous remission
Yeah, well
or they, it was the chemotherapy or radiation
These people, they don’t know what they do
They never, have never seen our results, and obviously they can’t believe that something like this could happen, but suddenly (laughs), in this room we are in now, we have some of
the top experts in the country, like people from FDA, who are expert oncologists, specialists
They’re working with you
Oh, they came here to inspect what we have
Yeah
They look at every scan of the people who are in clinical trials, and they decided that we have very good results
And is that stuff going to be published at some point ?
Ah, yes, we are publi, we are preparing this for publication, but, uh, obviously, in order to have the right results, you need, time, and most of our clinical trials began, approximately 10 years ago
So then we, if you would like to know what happen after, 10 years with these people
Mhmm
then you need to have a little time
So now we are preparing a number of, uh, publications, uh, and so this year we should have a number of publications, which will show final results
So far we didn’t have, final results, so were only interim reports, during the course of clinical trials
And with, uh, with brain tumors; because obviously, that’s an area that you’ve had
Yeah
huge suc, success rate
Yeah
What, why has that, do you think, as opposed to the other, types ?
Because that’s where we selected
Mhmm
We wanted to have something difficult
Ok (laughs)
Yeah
Because, uh, for the same reason that you mentioned
If you’d had something easier then, the doctors could say: “Well, this cancer usually disappears in its own”
And they are right
Some cancers may disappear on its own, in some higher percent than the others
Mhmm
But you know, brain tumors, you read, they never disappear on their own
Yeah
So that’s why we, decided to select such type of malignancies which are the most difficult
So what’s that been like when you’ve seen, I mean, I’ve seen obviously Jodi Fenton’s story
Yeah
Whe, whe, when you see these people’s
Yes
uh, scans
Yeah
and you see that that tumor has shrunk
Yeah
or broken down
Yeah
wha, what does that feel like ? (laughing)
Well, we see this all the time
(?) it just happens almost every day
Even today that we saw the patient, uh, who has pancreatic cancer, and after a few months of treatment it’s practically gone, and she is the wife of a doctor (laughs)
They came together, and that’s, that’s what we see practically every day
Ok
That must give you great strength to
Absolutely
continue
Absolutely, yes
So that’s something which is gratifying (laughs)
Yeah
What do you think the future is as far as drugs for cancer are concerned ?
I believe that, we are still at a very early stages of development in this area, but the future will be, with medications which are, highly specific, they will work on the genes that are involved in cancer
So, they will not harm normal part of the body, and, du, du, how to combine this medications will be established by, the special software, which will guide the doctors how to use proper medication for individual patient
I think this will be the, um, treatment that will be designed for, individual patient, and such design, it is not necessary to be done by the doctor
I think it should be, uh, certain computerized system which will put together, the best possible treatment plan, for a patient; which obviously needs to be checked and approved by the doctor
So I believe that this will be the future of medicine for the next, say, 40, and 50 years, coming up with better and better medications, which will be genomic switches, which will turn off, the cancerous process by regulating the genes which are involved; they simply will bring, the activity of these genes to normal levels, and finally, the new generation of medication which should work on cancerous stem cells, and, the medications which can kill cancerous stem cells without, uh, producing any harm to normal stem cells
So this will be the clue for, long-term control of cancer, because if you don’t eliminate, cancerous stem cells then the cancer will come back
Yeah
And that’s why chemotherapy, usually is unable to control cancer for a long time because, it’s pretty much powerless, ah, uh, regarding action on cancerous stem cells
But then after that, I think that we will make another, jump, and there will be, uh, procedures that will based on biophysics
Mmm
and by trying to get rid of, uh, the cancer and some of the diseases by effecting the body by using various, uh, wipes, which will be like magnetic wipes, it will be some other types of wipes, but using proper frequencies to, normalize all the cells in the body to normalize the activity of the genes
I think this will be a
Mmm
probably the next, uh, say 50 years of, uh, the end of this century when such (?)
So no one’s getting funding really, unless they’re doing it privately to,
being able to, isn’t that being able to research these areas, because funding really comes from pharmaceutical companies ?
Ah, well, most of this funding is from pharmaceutical companies, and also it is coming from the National Cancer Institute but, I think it’s regulated behind the scenes by the pharmaceutical companies
Eh, but they are still some researchers who are trying to do it on their own
Very few of them
I think there’s articles, in the Science magazine, some time ago which was talking about, uh, few of these researchers who are still trying to do, research on their own, and, I think, uh, I think there were probably some 4 or 5 of them in U.K. (laugh)
Yeah
still involved in research on their own
So what ah, what about the role of the mind ?
Do you think that, if someone has cancer and they wanna be well, do you think the way that someone thinks is important ?
Absolutely, that’s very important because, this, uh, can be translated, ah, to various biochemicals which can influence cancer
So obviously this is very important but, the question is how to, ah, direct this in the proper way
Ok
How to quantify this
So that’s something that should be done in the future
And nutrition as well
Yes, absolutely, yes
Why all have a lot of important chemicals in nutrition which can effectuate cancer, but regarding the mind you have to translate, uh, for instance, biophysical factors, in the brain, into biochemical factors, and certainly, that’s what the body’s doing all the time, but how to mobilize it, that’s a different story
Yeah
So if someone wants, if someone came to the Burzynski Clinic, wh, wh, what could they expect, to happen here?
Well 1st of all, we would like to give a selection, and we don’t want the people who we cannot treat to come
Uh, at this time we rather avoid, uh, patients in early stages of cancer, because with such patients, uh, what is used is standard of care treatment, and we prefer to refer them to, ah, different doctors
So we prefer to treat it once cancer patient, because, uh, they cannot be helped by the other doctors, and, uh, when they come to our clinic, we try to find out 1st, see if we can really help them or not, and, uh, once they come to the clinic, in most of the cases we can try to, help them, of course, and, uh, we put together, the personalized treatment plan, which is (?)
But all of those go through you
You look at every single one of those
Yes
I’m seeing every patient, who’s coming, if I’m
Yeah
if I’m around here, but, after that all the patients are really assigned to different senior physician and they’re responsible for daily care of patient here
How many people do you have, working here now ?
About 150 people here, yes
And you started with, well, just one (?)
Eh, I think really when we moved from Baylor College I had about 7 people at that time
Yeah
Yes, because, some of these doctors who are working together at Baylor College decided to leave together with me, including my wife, because she was also working at Baylor College
Yeah
Ok
Thank you
You’re welcome
My pleasure
Thank you so much
Thank you very much
Ok
======================================
======================================